



NCCP DOSE BANDING TABLES

DOSE BANDING FOR SYSTEMIC ANTI-CANCER THERAPY (SACT)

Version 7. November 2024

Table of Contents

NCCP DOSE BANDING TABLES	1
Introduction.....	4
DOSE BANDING TABLES – SYRINGES FOR SUBCUTANEOUS INJECTION:	5
AZACITIDINE SUBCUTANEOUS INJECTION	5
BORTEZOMIB SUBCUTANEOUS INJECTION	6
DOSE BANDING TABLES – SYRINGES FOR BOLUS INJECTION:	7
BLEOMYCIN SYRINGES	7
CYCLOPHOSPHAMIDE SYRINGES.....	8
DOXORUBICIN SYRINGES	9
EPIRUBICIN SYRINGES.....	10
5-FLUOROURACIL SYRINGES	11
METHOTREXATE SYRINGES.....	12
MITOMYCIN SYRINGES.....	13
DOSE BANDING TABLES – INFUSIONS FOR INTRAVENOUS ADMINISTRATION:	14
BENDAMUSTINE IV INFUSION	14
CABAZITAXEL IV INFUSION	15
CARFILZOMIB IV INFUSION	16
CARBOPLATIN IV INFUSION	17
CISPLATIN IV INFUSION.....	19
CYCLOPHOSPHAMIDE IV INFUSION.....	21
CYTARABINE IV INFUSION	23
DACARBAZINE INFUSION	25
DOCETAXEL IV INFUSION.....	26
DOXORUBICIN PEGYLATED LIPOSOMAL IV INFUSION	27
ETOPOSIDE IV INFUSION	28
5-FLUOROURACIL IV INFUSION	29
5-FLUOROURACIL INFUSORS	31
100mg/ml GEMCITABINE IV INFUSION	32
40mg/ml GEMCITABINE IV INFUSION	33
38mg/ml GEMCITABINE IV INFUSION	34

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

IFOSFAMIDE IV INFUSION	35
IRINOTECAN IV INFUSION	37
METHOTREXATE IV INFUSION	38
NAB-PACLITAXEL IV INFUSION	41
OXALIPLATIN IV INFUSION	42
PACLITAXEL IV INFUSION.....	43
PEMETREXED IV INFUSION.....	44
TOPOTECAN IV INFUSION	45
TRASTUZUMAB EMTANSINE IV INFUSION.....	46
VINBLASTINE IV INFUSION	47
VINCRIStINE IV INFUSION.....	48
VINORELBINE IV INFUSION	49
DOSE BANDING TABLES – MONOCLONALS FOR INTRAVENOUS INFUSION.....	50
MONOCLONALS - BEVACIZUMAB IV INFUSION.....	50
MONOCLONALS – CETUXIMAB IV INFUSION.....	52
MONOCLONALS - DARATUMUMAB INFUSION.....	53
MONOCLONALS – IPILIMUMAB IV INFUSION.....	54
MONOCLONALS – NIVOLUMAB IV INFUSION	56
MONOCLONALS – PANITUMUMAB IV INFUSION	57
MONOCLONALS – RITUXIMAB IV INFUSION	58
MONOCLONALS - TRASTUZUMAB IV INFUSION	59
DOSE BANDING TABLES – ORAL ANTI-CANCER MEDICATIONS:.....	60
CAPECITABINE	60
Version Control Table.....	61

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

Introduction

This document contains the NCCP National Dose Banding Tables.

The Dose Banding Tables have been developed in line with the NCCP Dose Banding Guidance document recommendations for dose banding calculations and have been agreed with ISMO and IHS. All dose bands contained in these tables are subject to local implementation and as deemed relevant to local practice.

The dose bands have been developed to cover the majority of potential doses to be given to patients. However, it is not expected that all these doses will be used commonly and that in fact, each site should identify the most likely doses applicable to their practice. The extreme ends of the Dose Banding Table can be applied to patient specific doses as and when they arise.

Each Dose Banding Table has a version number which will be updated if modifications to the table are required or if a new table has been developed.

Dose rounding has been applied to some of these tables as opposed to dose banding. This is in order to facilitate the nearest measurable volume.

Dose bands exceeding the targeted +/-5% variation from prescribed dose are highlighted in red.

COVID-19 Tables

Please note that there is an abridged series of NCCP National Dose Banding Tables which have been amended for the COVID-19 situation. The dose bands in these amended tables have been expanded up to a variance of 10% to reduce the number of dose bands available, facilitate optimal use of outsource provider and to minimise wastage.

These amended dose banding tables have been agreed with ISMO and IHS. All dose bands contained in these tables are subject to local implementation and as deemed relevant to local practice. Please refer to the NCCP Dose Banding documentation and full tables for more detail www.hse.ie/nccpdosebanding.

Review and Feedback

The Dose Banding Tables will be reviewed and updated as required. Please send any comments to oncologydrugs@cancercontrol.ie If you wish to suggest drugs suitable for dose banding, please outline the drug and the suggested dose bands and send to oncologydrugs@cancercontrol.ie

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOSE BANDING TABLES – SYRINGES FOR SUBCUTANEOUS INJECTION:

AZACITIDINE SUBCUTANEOUS INJECTION (Version 1)

The dose bands used in this table are constructed based on a 25mg/ml concentration of azaCITIDine.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
73 - 77	75	2.60% (Upr)" , -2.74% (Lwr)	2mg (Upr), -2mg (Lwr)
78 - 82	80	2.44% (Upr)" , -2.56% (Lwr)	2mg (Upr), -2mg (Lwr)
83 - 87	85	2.30% (Upr)" , -2.41% (Lwr)	2mg (Upr), -2mg (Lwr)
88 - 92	90	2.17% (Upr)" , -2.27% (Lwr)	2mg (Upr), -2mg (Lwr)
93 - 97	95	2.06% (Upr)" , -2.15% (Lwr)	2mg (Upr), -2mg (Lwr)
98 - 105	100	4.76% (Upr)" , -2.04% (Lwr)	5mg (Upr), -2mg (Lwr)
106 - 115	110	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)
116 - 125	120	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	130	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	140	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 157	150	4.46% (Upr)" , -2.74% (Lwr)	7mg (Upr), -4mg (Lwr)
158 - 172	165	4.07% (Upr)" , -4.43% (Lwr)	7mg (Upr), -7mg (Lwr)
173 - 189	180	4.76% (Upr)" , -4.05% (Lwr)	9mg (Upr), -7mg (Lwr)
190 - 212	200	5.66% (Upr)" , -5.26% (Lwr)	12mg (Upr), -10mg (Lwr)
213 - 237	225	5.06% (Upr)" , -5.63% (Lwr)	12mg (Upr), -12mg (Lwr)
238 - 262	250	4.58% (Upr)" , -5.04% (Lwr)	12mg (Upr), -12mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

BORTEZOMIB SUBCUTANEOUS INJECTION (Version 1)

The dose bands used in this table are constructed based on a 2.5mg/ml concentration of bortezomib.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
1.43 - 1.62	1.5	7.41% (Upr)" , -4.90% (Lwr)	0.12mg (Upr), -0.07mg (Lwr)
1.63 - 1.87	1.75	6.42% (Upr)" , -7.36% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
1.88 - 2.12	2	5.66% (Upr)" , -6.38% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
2.13 - 2.37	2.25	5.06% (Upr)" , -5.63% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
2.38 - 2.62	2.5	4.58% (Upr)" , -5.04% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
2.63 - 2.87	2.75	4.18% (Upr)" , -4.56% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
2.88 - 3.12	3	3.85% (Upr)" , -4.17% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
3.13 - 3.37	3.25	3.56% (Upr)" , -3.83% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
3.38 - 3.62	3.5	3.31% (Upr)" , -3.55% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
3.63 - 3.9	3.75	3.85% (Upr)" , -3.31% (Lwr)	0.15mg (Upr), -0.12mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOSE BANDING TABLES – SYRINGES FOR BOLUS INJECTION:

BLEOMYCIN SYRINGES (Version 3)

The dose bands used in this table are constructed based on a 3,000 International Units (IU)/ml concentration of bleomycin. Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (IU)	Maximum variation range (%)	Maximum variation range (IU)
5,800 - 6,299	6000	4.75% (Upr)" , -3.45% (Lwr)	299IU (Upr), -200IU (Lwr)
6,300 - 6,899	6600	4.33% (Upr)" , -4.76% (Lwr)	299IU (Upr), -300IU (Lwr)
6,900 - 7,499	7200	3.99% (Upr)" , -4.35% (Lwr)	299IU (Upr), -300IU (Lwr)
7,500 - 8,099	7800	3.69% (Upr)" , -4.00% (Lwr)	299IU (Upr), -300IU (Lwr)
8,100 - 8,699	8400	3.44% (Upr)" , -3.70% (Lwr)	299IU (Upr), -300IU (Lwr)
8,700 - 9,299	9000	3.22% (Upr)" , -3.45% (Lwr)	299IU (Upr), -300IU (Lwr)
9,300 - 9,899	9600	3.02% (Upr)" , -3.23% (Lwr)	299IU (Upr), -300IU (Lwr)
9,900 - 10,499	10200	2.85% (Upr)" , -3.03% (Lwr)	299IU (Upr), -300IU (Lwr)
10,500 - 11,099	10800	2.69% (Upr)" , -2.86% (Lwr)	299IU (Upr), -300IU (Lwr)
11,100 - 11,699	11400	2.56% (Upr)" , -2.70% (Lwr)	299IU (Upr), -300IU (Lwr)
11,700 - 12,589	12000	4.68% (Upr)" , -2.56% (Lwr)	589IU (Upr), -300IU (Lwr)
12,590 - 13,789	13200	4.27% (Upr)" , -4.85% (Lwr)	589IU (Upr), -610IU (Lwr)
13,790 - 14,989	14400	3.93% (Upr)" , -4.42% (Lwr)	589IU (Upr), -610IU (Lwr)
14,990 - 16,189	15600	3.64% (Upr)" , -4.07% (Lwr)	589IU (Upr), -610IU (Lwr)
16,190 - 17,389	16800	3.39% (Upr)" , -3.77% (Lwr)	589IU (Upr), -610IU (Lwr)
17,390 - 18,589	18000	3.17% (Upr)" , -3.51% (Lwr)	589IU (Upr), -610IU (Lwr)
18,590 - 19,789	19200	2.98% (Upr)" , -3.28% (Lwr)	589IU (Upr), -610IU (Lwr)
19,790 - 21,279	20400	4.13% (Upr)" , -3.08% (Lwr)	879IU (Upr), -610IU (Lwr)
21,280 - 23,079	22200	3.81% (Upr)" , -4.32% (Lwr)	879IU (Upr), -920IU (Lwr)
23,080 - 24,879	24000	3.53% (Upr)" , -3.99% (Lwr)	879IU (Upr), -920IU (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CYCLOPHOSPHAMIDE SYRINGES (Version 2)

The dose bands used in this table are constructed based on a 20mg/ml concentration of cyclophosphamide.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Syringes
380 - 429	400	6.76% (Upr)", -5.26% (Lwr)	29mg (Upr), -20mg (Lwr)	400mg
430 - 479	460	3.97% (Upr)", -6.98% (Lwr)	19mg (Upr), -30mg (Lwr)	200mg, 260mg
480 - 529	500	5.48% (Upr)", -4.17% (Lwr)	29mg (Upr), -20mg (Lwr)	500mg
530 - 579	560	3.28% (Upr)", -5.66% (Lwr)	19mg (Upr), -30mg (Lwr)	300mg, 260mg
580 - 629	600	4.61% (Upr)", -3.45% (Lwr)	29mg (Upr), -20mg (Lwr)	300mg x 2
630 - 679	660	2.80% (Upr)", -4.76% (Lwr)	19mg (Upr), -30mg (Lwr)	400mg, 260mg
680 - 729	700	3.98% (Upr)", -2.94% (Lwr)	29mg (Upr), -20mg (Lwr)	400mg, 300mg
730 - 779	760	2.44% (Upr)", -4.11% (Lwr)	19mg (Upr), -30mg (Lwr)	500mg, 260mg
780 - 829	800	3.50% (Upr)", -2.56% (Lwr)	29mg (Upr), -20mg (Lwr)	400mg x 2
830 - 879	860	2.16% (Upr)", -3.61% (Lwr)	19mg (Upr), -30mg (Lwr)	400mg, 200mg, 260mg
880 - 929	900	3.12% (Upr)", -2.27% (Lwr)	29mg (Upr), -20mg (Lwr)	500mg, 400mg
930 - 979	960	1.94% (Upr)", -3.23% (Lwr)	19mg (Upr), -30mg (Lwr)	500mg, 200mg, 260mg
980 - 1050	1000	4.76% (Upr)", -2.04% (Lwr)	50mg (Upr), -20mg (Lwr)	1000mg
1051 - 1150	1100	4.35% (Upr)", -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)	500mg, 400mg, 200mg
1151 - 1250	1200	4.00% (Upr)", -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 200mg
1251 - 1350	1300	3.70% (Upr)", -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 300mg
1351 - 1450	1400	3.45% (Upr)", -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 400mg
1451 - 1550	1500	3.23% (Upr)", -3.38% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 500mg
1551 - 1650	1600	3.03% (Upr)", -3.16% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 300mg, 300mg
1651 - 1750	1700	2.86% (Upr)", -2.97% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 300mg, 400mg
1751 - 1850	1800	2.70% (Upr)", -2.80% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 400mg, 400mg
1851 - 1950	1900	2.56% (Upr)", -2.65% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 500mg, 400mg

Suggested Stock Syringe Sizes: 200mg, 260mg, 300mg, 400mg, 500mg, 1000mg

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOXORUBICIN SYRINGES (Version 2)

The dose bands used in this table are constructed based on a 2mg/ml concentration of DOXOrubicin.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Syringes
31 - 33	32	3.03% (Upr)" , -3.23% (Lwr)	1mg (Upr), -1mg (Lwr)	
34 - 37	36	2.70% (Upr)" , -5.88% (Lwr)	1mg (Upr), -2mg (Lwr)	
38 - 42	40	4.76% (Upr)" , -5.26% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg
43 - 48	46	4.17% (Upr)" , -6.98% (Lwr)	2mg (Upr), -3mg (Lwr)	20mg, 26mg
49 - 53	50	5.66% (Upr)" , -2.04% (Lwr)	3mg (Upr), -1mg (Lwr)	50mg
54 - 58	56	3.45% (Upr)" , -3.70% (Lwr)	2mg (Upr), -2mg (Lwr)	30mg, 26mg
59 - 63	60	4.76% (Upr)" , -1.69% (Lwr)	3mg (Upr), -1mg (Lwr)	30mg x 2
64 - 68	66	2.94% (Upr)" , -3.13% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg, 26mg
69 - 73	70	4.11% (Upr)" , -1.45% (Lwr)	3mg (Upr), -1mg (Lwr)	40mg, 30mg
74 - 78	76	2.56% (Upr)" , -2.70% (Lwr)	2mg (Upr), -2mg (Lwr)	50mg, 26mg
79 - 83	80	3.61% (Upr)" , -1.27% (Lwr)	3mg (Upr), -1mg (Lwr)	50mg, 30mg
84 - 88	86	2.27% (Upr)" , -2.38% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg, 20mg, 26mg
89 - 93	90	3.23% (Upr)" , -1.12% (Lwr)	3mg (Upr), -1mg (Lwr)	40mg, 50mg
94 - 97	96	1.03% (Upr)" , -2.13% (Lwr)	1mg (Upr), -2mg (Lwr)	50mg, 20mg, 26mg
98 - 105	100	4.76% (Upr)" , -2.04% (Lwr)	5mg (Upr), -2mg (Lwr)	100mg
106 - 115	110	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)	50mg, 40mg, 20mg
116 - 125	120	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 20mg
126 - 135	130	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 30mg
136 - 145	140	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg
146 - 155	150	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 50mg
156 - 165	160	3.03% (Upr)" , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 30mg x 2
166 - 175	170	2.86% (Upr)" , -2.41% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg, 30mg
176 - 185	180	2.70% (Upr)" , -2.27% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 400mg x 2
186 - 195	190	2.56% (Upr)" , -2.15% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 50mg, 40mg
196 - 210	200	4.76% (Upr)" , -2.04% (Lwr)	10mg (Upr), -4mg (Lwr)	100mg x 2
211 - 230	220	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)	100mg x 2, 20mg x 1
231 - 250	240	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)	100mg x 2, 40mg x 1

Suggested Stock Syringe Sizes: 20mg, 26mg, 30mg, 40mg, 50mg, 100mg

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

EPIRUBICIN SYRINGES (Version 2)

The dose bands used in this table are constructed based on a 2mg/ml concentration of epiRUBicin.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Syringes
30 - 33	32	3.03% (Upr)" , -6.67% (Lwr)	1mg (Upr), -2mg (Lwr)	
34 - 37	36	2.70% (Upr)" , -5.88% (Lwr)	1mg (Upr), -2mg (Lwr)	
38 - 42	40	4.76% (Upr)" , -5.26% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg
43 - 47	46	2.13% (Upr)" , -6.98% (Lwr)	1mg (Upr), -3mg (Lwr)	20mg, 26mg
48 - 52	50	3.85% (Upr)" , -4.17% (Lwr)	2mg (Upr), -2mg (Lwr)	50mg
53 - 57	56	1.75% (Upr)" , -5.66% (Lwr)	1mg (Upr), -3mg (Lwr)	30mg, 26mg
58 - 62	60	3.23% (Upr)" , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)	30mg x 2
63 - 67	66	1.49% (Upr)" , -4.76% (Lwr)	1mg (Upr), -3mg (Lwr)	40mg, 26mg
68 - 72	70	2.78% (Upr)" , -2.94% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg, 30mg
73 - 77	76	1.30% (Upr)" , -4.11% (Lwr)	1mg (Upr), -3mg (Lwr)	50mg, 26mg
78 - 82	80	2.44% (Upr)" , -2.56% (Lwr)	2mg (Upr), -2mg (Lwr)	50mg, 30mg
83 - 87	86	1.15% (Upr)" , -3.61% (Lwr)	1mg (Upr), -3mg (Lwr)	40mg, 20mg, 26mg
88 - 92	90	2.17% (Upr)" , -2.27% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg, 50mg
93 - 97	96	1.03% (Upr)" , -3.23% (Lwr)	1mg (Upr), -3mg (Lwr)	50mg, 20mg, 26mg
98 - 105	100	4.76% (Upr)" , -2.04% (Lwr)	5mg (Upr), -2mg (Lwr)	100mg
106 - 115	110	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)	50mg, 40mg, 20mg
116 - 125	120	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 20mg
126 - 135	130	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 30mg
136 - 145	140	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg
146 - 155	150	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 50mg
156 - 165	160	3.03% (Upr)" , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 30mg x 2
166 - 175	170	2.86% (Upr)" , -2.41% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg, 30mg
176 - 185	180	2.70% (Upr)" , -2.27% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg x 2
186 - 195	190	2.56% (Upr)" , -2.15% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 50mg, 40mg
196 - 210	200	4.76% (Upr)" , -2.04% (Lwr)	10mg (Upr), -4mg (Lwr)	100mg x 2
211 - 230	220	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)	100mg x 2, 20mg x 1
231 - 250	240	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)	100mg x 2, 40mg x 1

Suggested Stock Syringe Sizes: 20mg, 26mg, 30mg, 40mg, 50mg, 100mg

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

5-FLUOROURACIL SYRINGES (Version 2)

The dose bands used in this table are constructed based on a 25mg/ml concentration of 5-fluorouracil.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Syringes
238 - 262	250	4.58% (Upr)" , -5.04% (Lwr)	12mg (Upr), -12mg (Lwr)	250mg
263 - 287	275	4.18% (Upr)" , -4.56% (Lwr)	12mg (Upr), -12mg (Lwr)	
288 - 312	300	3.85% (Upr)" , -4.17% (Lwr)	12mg (Upr), -12mg (Lwr)	300mg
313 - 337	325	3.56% (Upr)" , -3.83% (Lwr)	12mg (Upr), -12mg (Lwr)	
338 - 362	350	3.31% (Upr)" , -3.55% (Lwr)	12mg (Upr), -12mg (Lwr)	
363 - 387	375	3.10% (Upr)" , -3.31% (Lwr)	12mg (Upr), -12mg (Lwr)	
388 - 424	400	5.66% (Upr)" , -3.09% (Lwr)	24mg (Upr), -12mg (Lwr)	400mg
425 - 474	450	5.06% (Upr)" , -5.88% (Lwr)	24mg (Upr), -25mg (Lwr)	
475 - 525	500	4.76% (Upr)" , -5.26% (Lwr)	25mg (Upr), -25mg (Lwr)	500mg
526 - 575	550	4.35% (Upr)" , -4.56% (Lwr)	25mg (Upr), -24mg (Lwr)	300mg, 250mg
576 - 625	600	4.00% (Upr)" , -4.17% (Lwr)	25mg (Upr), -24mg (Lwr)	600mg
626 - 675	650	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)	400mg, 250mg
676 - 725	700	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)	400mg, 300mg
726 - 775	750	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)	500mg, 250mg
776 - 825	800	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)	400mg x 2
826 - 875	850	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)	600mg, 250mg
876 - 925	900	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)	500mg, 400mg
926 - 975	950	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)	400mg, 300mg, 250mg
976 - 1050	1000	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)	1000mg
1051 - 1150	1100	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)	500mg, 400mg, 200mg
1151 - 1250	1200	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 200mg
1251 - 1350	1300	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 300mg
1351 - 1450	1400	3.45% (Upr)" , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 400mg
1451 - 1550	1500	3.23% (Upr)" , -3.38% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 500mg

Suggested Stock Syringe Sizes: 250mg, 300mg, 400mg, 500mg, 600mg, 1000mg

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

METHOTREXATE SYRINGES (Version 1)

The dose bands used in this table are constructed based on a 25mg/ml concentration of methotrexate.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
29 - 31	30	3.23% (Upr)" , -3.45% (Lwr)	1mg (Upr), -1mg (Lwr)
32 - 33	32.5	1.52% (Upr)" , -1.56% (Lwr)	0.5mg (Upr), -0.5mg (Lwr)
34 - 36	35	2.78% (Upr)" , -2.94% (Lwr)	1mg (Upr), -1mg (Lwr)
37 - 38	37.5	1.32% (Upr)" , -1.35% (Lwr)	0.5mg (Upr), -0.5mg (Lwr)
39 - 42	40	4.76% (Upr)" , -2.56% (Lwr)	2mg (Upr), -1mg (Lwr)
43 - 47	45	4.26% (Upr)" , -4.65% (Lwr)	2mg (Upr), -2mg (Lwr)
48 - 52	50	3.85% (Upr)" , -4.17% (Lwr)	2mg (Upr), -2mg (Lwr)
53 - 57	55	3.51% (Upr)" , -3.77% (Lwr)	2mg (Upr), -2mg (Lwr)
58 - 62	60	3.23% (Upr)" , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)
63 - 67	65	2.99% (Upr)" , -3.17% (Lwr)	2mg (Upr), -2mg (Lwr)
68 - 72	70	2.78% (Upr)" , -2.94% (Lwr)	2mg (Upr), -2mg (Lwr)
73 - 77	75	2.60% (Upr)" , -2.74% (Lwr)	2mg (Upr), -2mg (Lwr)
78 - 82	80	2.44% (Upr)" , -2.56% (Lwr)	2mg (Upr), -2mg (Lwr)
83 - 87	85	2.30% (Upr)" , -2.41% (Lwr)	2mg (Upr), -2mg (Lwr)
88 - 92	90	2.17% (Upr)" , -2.27% (Lwr)	2mg (Upr), -2mg (Lwr)
93 - 97	95	2.06% (Upr)" , -2.15% (Lwr)	2mg (Upr), -2mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

MITOMYCIN SYRINGES (Version 1)

The dose bands used in this table are constructed based on a 1mg/ml concentration of mitoMYcin.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
2.90 - 3.19	3	5.96% (Upr)", -3.45% (Lwr)	0.19mg (Upr), -0.1mg (Lwr)
3.20 - 3.59	3.4	5.29% (Upr)", -6.25% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
3.60 - 3.99	3.8	4.76% (Upr)", -5.56% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
4.00 - 4.39	4.2	4.33% (Upr)", -5.00% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
4.40 - 4.79	4.6	3.97% (Upr)", -4.55% (Lwr)	0.19mg (Upr), -0.20mg (Lwr)
4.80 - 5.19	5	3.66% (Upr)", -4.17% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
5.20 - 5.59	5.4	3.40% (Upr)", -3.85% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
5.60 - 6.09	5.8	4.76% (Upr)", -3.57% (Lwr)	0.29mg (Upr), -0.2mg (Lwr)
6.10 - 6.69	6.4	4.33% (Upr)", -4.92% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
6.70 - 7.29	7	3.98% (Upr)", -4.48% (Lwr)	0.29mg (Upr), -0.3mg (Lwr)
7.30 - 7.99	7.6	4.88% (Upr)", -4.11% (Lwr)	0.39mg (Upr), -0.30mg (Lwr)
8.00 - 8.79	8.4	4.44% (Upr)", -5.00% (Lwr)	0.39mg (Upr), -0.4mg (Lwr)
8.80 - 9.59	9.2	4.07% (Upr)", -4.55% (Lwr)	0.39mg (Upr), -0.40mg (Lwr)
9.60 - 10.50	10	4.76% (Upr)", -4.17% (Lwr)	0.5mg (Upr), -0.4mg (Lwr)
10.51 - 11.50	11	4.35% (Upr)", -4.66% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
11.51 - 12.50	12	4.00% (Upr)", -4.26% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
12.51 - 13.50	13	3.70% (Upr)", -3.92% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
13.51 - 14.50	14	3.45% (Upr)", -3.63% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
14.51 - 15.50	15	3.23% (Upr)", -3.38% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
15.51 - 16.50	16	3.03% (Upr)", -3.16% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
16.51 - 17.50	17	2.86% (Upr)", -2.97% (Lwr)	0.50mg (Upr), -0.49mg (Lwr)
17.51 - 18.99	18	5.21% (Upr)", -2.80% (Lwr)	0.99mg (Upr), -0.49mg (Lwr)
19.00 - 21.00	20	4.76% (Upr)", -5.26% (Lwr)	1mg (Upr), -1mg (Lwr)
21.01 - 23.00	22	4.35% (Upr)", -4.71% (Lwr)	1mg (Upr), -0.99mg (Lwr)
23.01 - 25.00	24	4.00% (Upr)", -4.30% (Lwr)	1mg (Upr), -0.99mg (Lwr)
25.01 - 27.00	26	3.70% (Upr)", -3.96% (Lwr)	1mg (Upr), -0.99mg (Lwr)
27.01 - 29.00	28	3.45% (Upr)", -3.67% (Lwr)	1mg (Upr), -0.99mg (Lwr)
29.01 - 31.00	30	3.23% (Upr)", -3.41% (Lwr)	1mg (Upr), -0.99mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOSE BANDING TABLES – INFUSIONS FOR INTRAVENOUS ADMINISTRATION:

BENDAMUSTINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 2.5mg/ml concentration of bendamustine.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
73 - 77	75	2.60% (Upr)" , -2.74% (Lwr)	2mg (Upr), -2mg (Lwr)
78 - 82	80	2.44% (Upr)" , -2.56% (Lwr)	2mg (Upr), -2mg (Lwr)
83 - 87	85	2.30% (Upr)" , -2.41% (Lwr)	2mg (Upr), -2mg (Lwr)
88 - 92	90	2.17% (Upr)" , -2.27% (Lwr)	2mg (Upr), -2mg (Lwr)
93 - 97	95	2.06% (Upr)" , -2.15% (Lwr)	2mg (Upr), -2mg (Lwr)
98 - 105	100	4.76% (Upr)" , -2.04% (Lwr)	5mg (Upr), -2mg (Lwr)
106 - 115	110	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)
116 - 127	120	5.51% (Upr)" , -3.45% (Lwr)	7mg (Upr), -4mg (Lwr)
128 - 142	135	4.93% (Upr)" , -5.47% (Lwr)	7mg (Upr), -7mg (Lwr)
143 - 157	150	4.46% (Upr)" , -4.90% (Lwr)	7mg (Upr), -7mg (Lwr)
158 - 172	165	4.07% (Upr)" , -4.43% (Lwr)	7mg (Upr), -7mg (Lwr)
173 - 189	180	4.76% (Upr)" , -4.05% (Lwr)	9mg (Upr), -7mg (Lwr)
190 - 212	200	5.66% (Upr)" , -5.26% (Lwr)	12mg (Upr), -10mg (Lwr)
213 - 237	225	5.06% (Upr)" , -5.63% (Lwr)	12mg (Upr), -12mg (Lwr)
238 - 262	250	4.58% (Upr)" , -5.04% (Lwr)	12mg (Upr), -12mg (Lwr)
263 - 287	275	4.18% (Upr)" , -4.56% (Lwr)	12mg (Upr), -12mg (Lwr)
288 - 315	300	4.76% (Upr)" , -4.17% (Lwr)	15mg (Upr), -12mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CABAZITAXEL IV INFUSION (Version1)

The dose bands used in this table are constructed based on a 10mg/ml concentration of cabazitaxel.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
21 - 22.9	22	3.93% (Upr)" , -4.76% (Lwr)	0.9mg (Upr), -1mg (Lwr)
23 - 24.9	24	3.61% (Upr)" , -4.35% (Lwr)	0.9mg (Upr), -1mg (Lwr)
25 - 26.9	26	3.35% (Upr)" , -4.00% (Lwr)	0.9mg (Upr), -1mg (Lwr)
27 - 28.9	28	3.11% (Upr)" , -3.70% (Lwr)	0.9mg (Upr), -1mg (Lwr)
29 - 30.9	30	2.91% (Upr)" , -3.45% (Lwr)	0.9mg (Upr), -1mg (Lwr)
31 - 32.9	32	2.74% (Upr)" , -3.23% (Lwr)	0.9mg (Upr), -1mg (Lwr)
33 - 34.9	34	2.58% (Upr)" , -3.03% (Lwr)	0.9mg (Upr), -1mg (Lwr)
35 - 37.9	36	5.01% (Upr)" , -2.86% (Lwr)	1.9mg (Upr), -1mg (Lwr)
38 - 41.9	40	4.53% (Upr)" , -5.26% (Lwr)	1.9mg (Upr), -2mg (Lwr)
42 - 45.9	44	4.14% (Upr)" , -4.76% (Lwr)	1.9mg (Upr), -2mg (Lwr)
46 - 49.9	48	3.81% (Upr)" , -4.35% (Lwr)	1.9mg (Upr), -2mg (Lwr)
50 - 53.9	52	3.53% (Upr)" , -4.00% (Lwr)	1.9mg (Upr), -2mg (Lwr)
54 - 57.9	56	3.28% (Upr)" , -3.70% (Lwr)	1.9mg (Upr), -2mg (Lwr)
58 - 62.9	60	4.61% (Upr)" , -3.45% (Lwr)	2.9mg (Upr), -2mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CARFILZOMIB IV INFUSION (Version1)

The dose bands used in this table are constructed based on a 2mg/ml concentration of carfilzomib.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
31 - 33	32	3.03% (Upr)", -3.23% (Lwr)	1mg (Upr), -1mg (Lwr)
34 - 37	36	2.70% (Upr)", 5.88% (Lwr)	1mg (Upr), -2mg (Lwr)
38 - 41	40	2.44% (Upr)", 5.26% (Lwr)	1mg (Upr), -2mg (Lwr)
42 - 45	44	2.22% (Upr)", -4.76% (Lwr)	1mg (Upr), -2mg (Lwr)
46 - 49	48	2.04% (Upr)", -4.35% (Lwr)	1mg (Upr), -2mg (Lwr)
50 - 53	52	1.89% (Upr)", -4.00% (Lwr)	1mg (Upr), -2mg (Lwr)
54 - 57	56	1.75% (Upr)", -3.70% (Lwr)	1mg (Upr), -2mg (Lwr)
58 - 61	60	1.64% (Upr)", -3.45% (Lwr)	1mg (Upr), -2mg (Lwr)
62 - 65	64	1.54% (Upr)", -3.23% (Lwr)	1mg (Upr), -2mg (Lwr)
66 - 70	68	2.86% (Upr)", -3.03% (Lwr)	2mg (Upr), -2mg (Lwr)
71 - 76	74	2.63% (Upr)", -4.23% (Lwr)	2mg (Upr), -3mg (Lwr)
77 - 82	80	2.44% (Upr)", -3.90% (Lwr)	2mg (Upr), -3mg (Lwr)
83 - 88	86	2.27% (Upr)", -3.61% (Lwr)	2mg (Upr), -3mg (Lwr)
89 - 94	92	2.13% (Upr)", -3.37% (Lwr)	2mg (Upr), -3mg (Lwr)
95 - 100	98	2.00% (Upr)", -3.16% (Lwr)	2mg (Upr), -3mg (Lwr)
101 - 106	104	1.89% (Upr)", -2.97% (Lwr)	2mg (Upr), -3mg (Lwr)
107 - 115	110	4.35% (Upr)", -2.80% (Lwr)	5mg (Upr), -3mg (Lwr)
116 - 125	120	4.00% (Upr)", -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	130	3.70% (Upr)", -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	140	3.45% (Upr)", -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 155	150	3.23% (Upr)", -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CARBOPLATIN IV INFUSION (Version 4)

The dose bands used in this table are constructed based on a 10mg/ml concentration of CARBOplatin.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
57 - 62	60	3.23% (Upr)" , -5.26% (Lwr)	2mg (Upr), -3mg (Lwr)
63 - 69	66	4.35% (Upr)" , -4.76% (Lwr)	3mg (Upr), -3mg (Lwr)
70 - 77	74	3.90% (Upr)" , -5.71% (Lwr)	3mg (Upr), -4mg (Lwr)
78 - 85	82	3.53% (Upr)" , -5.13% (Lwr)	3mg (Upr), -4mg (Lwr)
86 - 94	90	4.26% (Upr)" , -4.65% (Lwr)	4mg (Upr), -4mg (Lwr)
95 - 104	100	3.85% (Upr)" , -5.26% (Lwr)	4mg (Upr), -5mg (Lwr)
105 - 114	110	3.51% (Upr)" , -4.76% (Lwr)	4mg (Upr), -5mg (Lwr)
115 - 124	120	3.23% (Upr)" , -4.35% (Lwr)	4mg (Upr), -5mg (Lwr)
125 - 134	130	2.99% (Upr)" , -4.00% (Lwr)	4mg (Upr), -5mg (Lwr)
135 - 144	140	2.78% (Upr)" , -3.70% (Lwr)	4mg (Upr), -5mg (Lwr)
145 - 154	150	2.60% (Upr)" , -3.45% (Lwr)	4mg (Upr), -5mg (Lwr)
155 - 169	160	5.33% (Upr)" , -3.23% (Lwr)	9mg (Upr), -5mg (Lwr)
170 - 189	180	4.76% (Upr)" , -5.88% (Lwr)	9mg (Upr), -10mg (Lwr)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	280	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 305	300	1.64% (Upr)" , -3.45% (Lwr)	5mg (Upr), -10mg (Lwr)
306 - 324	310	4.32% (Upr)" , -1.31% (Lwr)	14mg (Upr), -4mg (Lwr)
325 - 355	340	4.23% (Upr)" , -4.62% (Lwr)	15mg (Upr), -15mg (Lwr)
356 - 385	370	3.90% (Upr)" , -3.93% (Lwr)	15mg (Upr), -14mg (Lwr)
386 - 420	400	4.76% (Upr)" , -3.63% (Lwr)	20mg (Upr), -14mg (Lwr)
421 - 445	440	1.12% (Upr)" , -4.51% (Lwr)	5mg (Upr), -19mg (Lwr)
446 - 460	450	2.17% (Upr)" , -0.90% (Lwr)	10mg (Upr), -4mg (Lwr)
461 - 500	480	4.00% (Upr)" , -4.12% (Lwr)	20mg (Upr), -19mg (Lwr)
501 - 540	520	3.70% (Upr)" , -3.79% (Lwr)	20mg (Upr), -19mg (Lwr)
541 - 580	560	3.45% (Upr)" , -3.51% (Lwr)	20mg (Upr), -19mg (Lwr)
581 - 625	600	4.00% (Upr)" , -3.27% (Lwr)	25mg (Upr), -19mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CARBOPLATIN IV INFUSION (Version 4) continued			
626 - 680	650	4.41% (Upr)" , -3.83% (Lwr)	30mg (Upr), -24mg (Lwr)
681 - 730	710	2.74% (Upr)" , -4.26% (Lwr)	20mg (Upr), -29mg (Lwr)
731 - 760	750	1.32% (Upr)" , -2.60% (Lwr)	10mg (Upr), -19mg (Lwr)
761 - 810	770	4.94% (Upr)" , -1.18% (Lwr)	40mg (Upr), -9mg (Lwr)
811 - 880	850	3.41% (Upr)" , -4.81% (Lwr)	30mg (Upr), -39mg (Lwr)
881 - 910	900	1.10% (Upr)" , -2.16% (Lwr)	10mg (Upr), -19mg (Lwr)
911 - 975	930	4.62% (Upr)" , -2.09% (Lwr)	45mg (Upr), -19mg (Lwr)
976 - 1040	1020	1.92% (Upr)" , -4.51% (Lwr)	20mg (Upr), -44mg (Lwr)
1041 - 1070	1050	1.87% (Upr)" , -0.86% (Lwr)	20mg (Upr), -9mg (Lwr)
1071 - 1170	1120	4.27% (Upr)" , -4.58% (Lwr)	50mg (Upr), -49mg (Lwr)
1171 - 1280	1220	4.69% (Upr)" , -4.18% (Lwr)	60mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CISPLATIN IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 1mg/ml concentration of CISplatin.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
19 - 21	20	4.76% (Upr)" , -5.26% (Lwr)	1mg (Upr), -1mg (Lwr)
22 - 24	23	4.17% (Upr)" , -4.55% (Lwr)	1mg (Upr), -1mg (Lwr)
25 - 27	26	3.70% (Upr)" , -4.00% (Lwr)	1mg (Upr), -1mg (Lwr)
28 - 30	29	3.33% (Upr)" , -3.57% (Lwr)	1mg (Upr), -1mg (Lwr)
31 - 33	32	3.03% (Upr)" , -3.23% (Lwr)	1mg (Upr), -1mg (Lwr)
34 - 37	35	5.41% (Upr)" , -2.94% (Lwr)	2mg (Upr), -1mg (Lwr)
38 - 42	40	4.76% (Upr)" , -5.26% (Lwr)	2mg (Upr), -2mg (Lwr)
43 - 47	45	4.26% (Upr)" , -4.65% (Lwr)	2mg (Upr), -2mg (Lwr)
48 - 52	50	3.85% (Upr)" , -4.17% (Lwr)	2mg (Upr), -2mg (Lwr)
53 - 57	55	3.51% (Upr)" , -3.77% (Lwr)	2mg (Upr), -2mg (Lwr)
58 - 62	60	3.23% (Upr)" , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)
63 - 68	66	2.94% (Upr)" , -4.76% (Lwr)	2mg (Upr), -3mg (Lwr)
69 - 76	72	5.26% (Upr)" , -4.35% (Lwr)	4mg (Upr), -3mg (Lwr)
77 - 84	80	4.76% (Upr)" , -3.90% (Lwr)	4mg (Upr), -3mg (Lwr)
85 - 94	90	4.26% (Upr)" , -5.88% (Lwr)	4mg (Upr), -5mg (Lwr)
95 - 104	100	3.85% (Upr)" , -5.26% (Lwr)	4mg (Upr), -5mg (Lwr)
105 - 114	110	3.51% (Upr)" , -4.76% (Lwr)	4mg (Upr), -5mg (Lwr)
115 - 124	120	3.23% (Upr)" , -4.35% (Lwr)	4mg (Upr), -5mg (Lwr)
125 - 134	130	2.99% (Upr)" , -4.00% (Lwr)	4mg (Upr), -5mg (Lwr)
135 - 144	140	2.78% (Upr)" , -3.70% (Lwr)	4mg (Upr), -5mg (Lwr)
145 - 154	150	2.60% (Upr)" , -3.45% (Lwr)	4mg (Upr), -5mg (Lwr)
155 - 169	160	5.33% (Upr)" , -3.23% (Lwr)	9mg (Upr), -5mg (Lwr)
170 - 189	180	4.76% (Upr)" , -5.88% (Lwr)	9mg (Upr), -10mg (Lwr)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
245 - 265	255*	3.77% (Upr)" , -4.08% (Lwr)	10mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 294	280	4.76% (Upr)" , -3.70% (Lwr)	14mg (Upr), -10mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CISPLATIN IV INFUSION (Version 2) continued			
295 - 324	310	4.32% (Upr)" , -5.08% (Lwr)	14mg (Upr), -15mg (Lwr)

*Please note: A 255mg Dose Band has been included as this is the maximum dose that external compounders will add to a Baxter Viaflo bag and this facilitates dispensing in NCIS.

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CYCLOPHOSPHAMIDE IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 20mg/ml concentration of cyclophosphamide.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	280	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	300	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	320	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	340	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 369	360	2.44% (Upr)" , -2.86% (Lwr)	9mg (Upr), -10mg (Lwr)
370 - 399	380	4.76% (Upr)" , -2.70% (Lwr)	19mg (Upr), -10mg (Lwr)
400 - 439	420	4.33% (Upr)" , -5.00% (Lwr)	19mg (Upr), -20mg (Lwr)
440 - 479	460	3.97% (Upr)" , -4.55% (Lwr)	19mg (Upr), -20mg (Lwr)
480 - 529	500	5.48% (Upr)" , -4.17% (Lwr)	29mg (Upr), -20mg (Lwr)
530 - 579	560	3.28% (Upr)" , -5.66% (Lwr)	19mg (Upr), -30mg (Lwr)
580 - 629	600	4.61% (Upr)" , -3.45% (Lwr)	29mg (Upr), -20mg (Lwr)
630 - 689	660	4.21% (Upr)" , -4.76% (Lwr)	29mg (Upr), -30mg (Lwr)
690 - 750	720	4.00% (Upr)" , -4.35% (Lwr)	30mg (Upr), -30mg (Lwr)
751 - 810	780	3.70% (Upr)" , -3.86% (Lwr)	30mg (Upr), -29mg (Lwr)
811 - 880	840	4.55% (Upr)" , -3.58% (Lwr)	40mg (Upr), -29mg (Lwr)
881 - 960	920	4.17% (Upr)" , -4.43% (Lwr)	40mg (Upr), -39mg (Lwr)
961 - 1050	1000	4.76% (Upr)" , -4.06% (Lwr)	50mg (Upr), -39mg (Lwr)
1051 - 1150	1100	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	1300	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1470	1400	4.76% (Upr)" , -3.63% (Lwr)	70mg (Upr), -49mg (Lwr)
1471 - 1600	1540	3.75% (Upr)" , -4.69% (Lwr)	60mg (Upr), -69mg (Lwr)
1601 - 1740	1680	3.45% (Upr)" , -4.93% (Lwr)	60mg (Upr), -79mg (Lwr)
1741 - 1900	1820	4.21% (Upr)" , -4.54% (Lwr)	80mg (Upr), -79mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CYCLOPHOSPHAMIDE IV INFUSION Version 2 (continued)			
1901 - 2100	2000	4.76% (Upr)" , -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)
2101 - 2300	2200	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2520	2400	4.76% (Upr)" , -4.30% (Lwr)	120mg (Upr), -99mg (Lwr)
2521 - 2760	2640	4.35% (Upr)" , -4.72% (Lwr)	120mg (Upr), -119mg (Lwr)
2761 - 3040	2900	4.61% (Upr)" , -5.03% (Lwr)	140mg (Upr), -139mg (Lwr)
3041 - 3350	3200	4.48% (Upr)" , -5.23% (Lwr)	150mg (Upr), -159mg (Lwr)
3351 - 3650	3500	4.11% (Upr)" , -4.45% (Lwr)	150mg (Upr), -149mg (Lwr)
3651 - 3990	3800	4.76% (Upr)" , -4.08% (Lwr)	190mg (Upr), -149mg (Lwr)
3991 - 4400	4200	4.55% (Upr)" , -5.24% (Lwr)	200mg (Upr), -209mg (Lwr)
4401 - 4800	4600	4.17% (Upr)" , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5250	5000	4.76% (Upr)" , -4.14% (Lwr)	250mg (Upr), -199mg (Lwr)
5251 - 5750	5500	4.35% (Upr)" , -4.74% (Lwr)	250mg (Upr), -249mg (Lwr)
5751 - 6250	6000	4.00% (Upr)" , -4.33% (Lwr)	250mg (Upr), -249mg (Lwr)
6251 - 6750	6500	3.70% (Upr)" , -3.98% (Lwr)	250mg (Upr), -249mg (Lwr)
6751 - 7250	7000	3.45% (Upr)" , -3.69% (Lwr)	250mg (Upr), -249mg (Lwr)
7251 - 7750	7500	3.23% (Upr)" , -3.43% (Lwr)	250mg (Upr), -249mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CYTARABINE IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 100mg/ml concentration of cytarabine.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
125 - 134	130	2.99% (Upr)", -4.00% (Lwr)	4mg (Upr), -5mg (Lwr)
135 - 144	140	2.78% (Upr)", -3.70% (Lwr)	4mg (Upr), -5mg (Lwr)
145 - 154	150	2.60% (Upr)", -3.45% (Lwr)	4mg (Upr), -5mg (Lwr)
155 - 169	160	5.33% (Upr)", -3.23% (Lwr)	9mg (Upr), -5mg (Lwr)
170 - 189	180	4.76% (Upr)", -5.88% (Lwr)	9mg (Upr), -10mg (Lwr)
190 - 209	200	4.31% (Upr)", -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)", -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)", -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)", -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	280	3.11% (Upr)", -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	300	2.91% (Upr)", -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	320	2.74% (Upr)", -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	340	2.58% (Upr)", -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	360	5.01% (Upr)", -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 419	400	4.53% (Upr)", -5.26% (Lwr)	19mg (Upr), -20mg (Lwr)
420 - 459	440	4.14% (Upr)", -4.76% (Lwr)	19mg (Upr), -20mg (Lwr)
460 - 499	480	3.81% (Upr)", -4.35% (Lwr)	19mg (Upr), -20mg (Lwr)
500 - 539	520	3.53% (Upr)", -4.00% (Lwr)	19mg (Upr), -20mg (Lwr)
540 - 579	560	3.28% (Upr)", -3.70% (Lwr)	19mg (Upr), -20mg (Lwr)
580 - 629	600	4.61% (Upr)", -3.45% (Lwr)	29mg (Upr), -20mg (Lwr)
630 - 689	660	4.21% (Upr)", -4.76% (Lwr)	29mg (Upr), -30mg (Lwr)
690 - 749	720	3.87% (Upr)", -4.35% (Lwr)	29mg (Upr), -30mg (Lwr)
750 - 819	780	4.76% (Upr)", -4.00% (Lwr)	39mg (Upr), -30mg (Lwr)
820 - 899	860	4.34% (Upr)", -4.88% (Lwr)	39mg (Upr), -40mg (Lwr)
900 - 979	940	3.98% (Upr)", -4.44% (Lwr)	39mg (Upr), -40mg (Lwr)
980 - 1050	1000	4.76% (Upr)", -2.04% (Lwr)	50mg (Upr), -20mg (Lwr)
1051 - 1150	1100	4.35% (Upr)", -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)", -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	1300	3.70% (Upr)", -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CYTARABINE IV INFUSION (Version 2) continued			
1351 - 1450	1400	3.45% (Upr)" , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)
1451 - 1550	1500	3.23% (Upr)" , -3.38% (Lwr)	50mg (Upr), -49mg (Lwr)
1551 - 1650	1600	3.03% (Upr)" , -3.16% (Lwr)	50mg (Upr), -49mg (Lwr)
1651 - 1750	1700	2.86% (Upr)" , -2.97% (Lwr)	50mg (Upr), -49mg (Lwr)
1751 - 1900	1800	5.26% (Upr)" , -2.80% (Lwr)	100mg (Upr), -49mg (Lwr)
1901 - 2100	2000	4.76% (Upr)" , -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)
2101 - 2300	2200	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2520	2400	4.76% (Upr)" , -4.30% (Lwr)	120mg (Upr), -99mg (Lwr)
2521 - 2750	2600	5.45% (Upr)" , -3.13% (Lwr)	150mg (Upr), -79mg (Lwr)
2751 - 3050	2900	4.92% (Upr)" , -5.42% (Lwr)	150mg (Upr), -149mg (Lwr)
3051 - 3350	3200	4.48% (Upr)" , -4.88% (Lwr)	150mg (Upr), -149mg (Lwr)
3351 - 3650	3500	4.11% (Upr)" , -4.45% (Lwr)	150mg (Upr), -149mg (Lwr)
3651 - 3990	3800	4.76% (Upr)" , -4.08% (Lwr)	190mg (Upr), -149mg (Lwr)
3991 - 4400	4200	4.55% (Upr)" , -5.24% (Lwr)	200mg (Upr), -209mg (Lwr)
4401 - 4800	4600	4.17% (Upr)" , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5250	5000	4.76% (Upr)" , -4.14% (Lwr)	250mg (Upr), -199mg (Lwr)
5251 - 5750	5500	4.35% (Upr)" , -4.74% (Lwr)	250mg (Upr), -249mg (Lwr)
5751 - 6250	6000	4.00% (Upr)" , -4.33% (Lwr)	250mg (Upr), -249mg (Lwr)
6251 - 6750	6500	3.70% (Upr)" , -3.98% (Lwr)	250mg (Upr), -249mg (Lwr)
6751 - 7250	7000	3.45% (Upr)" , -3.69% (Lwr)	250mg (Upr), -249mg (Lwr)
7251 - 7750	7500	3.23% (Upr)" , -3.43% (Lwr)	250mg (Upr), -249mg (Lwr)
7751 - 8250	8000	3.03% (Upr)" , -3.21% (Lwr)	250mg (Upr), -249mg (Lwr)
8251 - 8750	8500	2.86% (Upr)" , -3.02% (Lwr)	250mg (Upr), -249mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DACARBAZINE INFUSION (Version 1)

The dose bands used in this table are constructed based on a 20mg/ml concentration of dacarbazine.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
290 - 309	300	2.91% (Upr)", -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	320	2.74% (Upr)", -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 359	340	5.29% (Upr)", -3.03% (Lwr)	19mg (Upr), -10mg (Lwr)
360 - 399	380	4.76% (Upr)", -5.56% (Lwr)	19mg (Upr), -20mg (Lwr)
400 - 439	420	4.33% (Upr)", -5.00% (Lwr)	19mg (Upr), -20mg (Lwr)
440 - 479	460	3.97% (Upr)", -4.55% (Lwr)	19mg (Upr), -20mg (Lwr)
480 - 529	500	5.48% (Upr)", -4.17% (Lwr)	29mg (Upr), -20mg (Lwr)
530 - 579	560	3.28% (Upr)", -5.66% (Lwr)	19mg (Upr), -30mg (Lwr)
580 - 629	600	4.61% (Upr)", -3.45% (Lwr)	29mg (Upr), -20mg (Lwr)
630 - 689	660	4.21% (Upr)", -4.76% (Lwr)	29mg (Upr), -30mg (Lwr)
690 - 750	720	4.00% (Upr)", -4.35% (Lwr)	30mg (Upr), -30mg (Lwr)
751 - 810	780	3.70% (Upr)", -3.86% (Lwr)	30mg (Upr), -29mg (Lwr)
811 - 880	840	4.55% (Upr)", -3.58% (Lwr)	40mg (Upr), -29mg (Lwr)
881 - 960	920	4.17% (Upr)", -4.43% (Lwr)	40mg (Upr), -39mg (Lwr)
961 - 1050	1000	4.76% (Upr)", -4.06% (Lwr)	50mg (Upr), -39mg (Lwr)
1051 - 1150	1100	4.35% (Upr)", -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)", -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	1300	3.70% (Upr)", -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1470	1400	4.76% (Upr)", -3.63% (Lwr)	70mg (Upr), -49mg (Lwr)
1471 - 1600	1540	3.75% (Upr)", -4.69% (Lwr)	60mg (Upr), -69mg (Lwr)
1601 - 1740	1680	3.45% (Upr)", -4.93% (Lwr)	60mg (Upr), -79mg (Lwr)
1741 - 1900	1820	4.21% (Upr)", -4.54% (Lwr)	80mg (Upr), -79mg (Lwr)
1901 - 2100	2000	4.76% (Upr)", -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)
2101 - 2300	2200	4.35% (Upr)", -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2500	2400	4.00% (Upr)", -4.30% (Lwr)	100mg (Upr), -99mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOCETAXEL IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 20mg/ml concentration of DOCETaxel.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
31 - 33	32	3.03% (Upr)" , -3.23% (Lwr)	1mg (Upr), -1mg (Lwr)
34 - 37	36	2.70% (Upr)" , -5.88% (Lwr)	1mg (Upr), -2mg (Lwr)
38 - 42	40	4.76% (Upr)" , -5.26% (Lwr)	2mg (Upr), -2mg (Lwr)
43 - 46	44	4.35% (Upr)" , -2.33% (Lwr)	2mg (Upr), -1mg (Lwr)
47 - 50	48	4.00% (Upr)" , -2.13% (Lwr)	2mg (Upr), -1mg (Lwr)
51 - 54	52	3.70% (Upr)" , -1.96% (Lwr)	2mg (Upr), -1mg (Lwr)
55 - 58	56	3.45% (Upr)" , -1.82% (Lwr)	2mg (Upr), -1mg (Lwr)
59 - 62	60	3.23% (Upr)" , -1.69% (Lwr)	2mg (Upr), -1mg (Lwr)
63 - 66	64	3.03% (Upr)" , -1.59% (Lwr)	2mg (Upr), -1mg (Lwr)
67 - 70	68	2.86% (Upr)" , -1.49% (Lwr)	2mg (Upr), -1mg (Lwr)
71 - 75	72	4.00% (Upr)" , -1.41% (Lwr)	3mg (Upr), -1mg (Lwr)
76 - 84	80	4.76% (Upr)" , -5.26% (Lwr)	4mg (Upr), -4mg (Lwr)
85 - 92	88	4.35% (Upr)" , -3.53% (Lwr)	4mg (Upr), -3mg (Lwr)
93 - 100	96	4.00% (Upr)" , -3.23% (Lwr)	4mg (Upr), -3mg (Lwr)
101 - 108	104	3.70% (Upr)" , -2.97% (Lwr)	4mg (Upr), -3mg (Lwr)
109 - 116	112	3.45% (Upr)" , -2.75% (Lwr)	4mg (Upr), -3mg (Lwr)
117 - 126	120	4.76% (Upr)" , -2.56% (Lwr)	6mg (Upr), -3mg (Lwr)
127 - 138	132	4.35% (Upr)" , -3.94% (Lwr)	6mg (Upr), -5mg (Lwr)
139 - 150	144	4.00% (Upr)" , -3.60% (Lwr)	6mg (Upr), -5mg (Lwr)
151 - 162	156	3.70% (Upr)" , -3.31% (Lwr)	6mg (Upr), -5mg (Lwr)
163 - 174	168	3.45% (Upr)" , -3.07% (Lwr)	6mg (Upr), -5mg (Lwr)
175 - 189	180	4.76% (Upr)" , -2.86% (Lwr)	9mg (Upr), -5mg (Lwr)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOXORUBICIN PEGYLATED LIPOSOMAL IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 2mg/ml concentration of DOXOrubicin pegylated liposomal.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
13 - 14.9	14	6.04% (Upr)", -7.69% (Lwr)	0.90mg (Upr), -1.00mg (Lwr)
15 - 16.9	16	5.33% (Upr)", -6.67% (Lwr)	0.90mg (Upr), -1.00mg (Lwr)
17 - 18.9	18	4.76% (Upr)", -5.88% (Lwr)	0.90mg (Upr), -1.00mg (Lwr)
19 - 20.9	20	4.31% (Upr)", -5.26% (Lwr)	0.90mg (Upr), -1.00mg (Lwr)
21 - 22.9	22	3.93% (Upr)", -4.76% (Lwr)	0.90mg (Upr), -1.00mg (Lwr)
23 - 24.9	24	3.61% (Upr)", -4.35% (Lwr)	0.90mg (Upr), -1.00mg (Lwr)
25 - 26.9	26	3.35% (Upr)", -4.00% (Lwr)	0.90mg (Upr), -1.00mg (Lwr)
27 - 28.9	28	3.11% (Upr)", -3.70% (Lwr)	0.90mg (Upr), -1.00mg (Lwr)
29 - 30.9	30	2.91% (Upr)", -3.45% (Lwr)	0.90mg (Upr), -1.00mg (Lwr)
31 - 33.9	32	5.60% (Upr)", -3.23% (Lwr)	1.90mg (Upr), -1.00mg (Lwr)
34 - 37.9	36	5.01% (Upr)", -5.88% (Lwr)	1.90mg (Upr), -2.00mg (Lwr)
38 - 41.9	40	4.53% (Upr)", -5.26% (Lwr)	1.90mg (Upr), -2.00mg (Lwr)
42 - 45.9	44	4.14% (Upr)", -4.76% (Lwr)	1.90mg (Upr), -2.00mg (Lwr)
46 - 49.9	48	3.81% (Upr)", -4.35% (Lwr)	1.90mg (Upr), -2.00mg (Lwr)
50 - 53.9	52	3.53% (Upr)", -4.00% (Lwr)	1.90mg (Upr), -2.00mg (Lwr)
54 - 57.9	56	3.28% (Upr)", -3.70% (Lwr)	1.90mg (Upr), -2.00mg (Lwr)
58 - 61.9	60	3.07% (Upr)", -3.45% (Lwr)	1.90mg (Upr), -2.00mg (Lwr)
62 - 65.9	64	2.88% (Upr)", -3.23% (Lwr)	1.90mg (Upr), -2.00mg (Lwr)
66 - 70.9	68	4.09% (Upr)", -3.03% (Lwr)	2.90mg (Upr), -2.00mg (Lwr)
71 - 76.9	74	3.77% (Upr)", -4.23% (Lwr)	2.90mg (Upr), -3.00mg (Lwr)
77 - 82.9	80	3.50% (Upr)", -3.90% (Lwr)	2.90mg (Upr), -3.00mg (Lwr)
83 - 88.9	86	3.26% (Upr)", -3.61% (Lwr)	2.90mg (Upr), -3.00mg (Lwr)
89 - 94.9	92	3.06% (Upr)", -3.37% (Lwr)	2.90mg (Upr), -3.00mg (Lwr)
95 - 100.9	98	2.87% (Upr)", -3.16% (Lwr)	2.90mg (Upr), -3.00mg (Lwr)
101 - 106.9	104	2.71% (Upr)", -2.97% (Lwr)	2.90mg (Upr), -3.00mg (Lwr)
107 - 114.9	110	4.26% (Upr)", -2.80% (Lwr)	4.90mg (Upr), -3.00mg (Lwr)
115 - 125.9	120	4.69% (Upr)", -4.35% (Lwr)	5.90mg (Upr), -5.00mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

ETOPOSIDE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 20mg/ml concentration of etoposide.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
58 - 62	60	3.23% (Upr)" , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)
63 - 66	64	3.03% (Upr)" , -1.59% (Lwr)	2mg (Upr), -1mg (Lwr)
67 - 70	68	2.86% (Upr)" , -1.49% (Lwr)	2mg (Upr), -1mg (Lwr)
71 - 76	72	5.26% (Upr)" , -1.41% (Lwr)	4mg (Upr), -1mg (Lwr)
77 - 84	80	4.76% (Upr)" , -3.90% (Lwr)	4mg (Upr), -3mg (Lwr)
85 - 92	88	4.35% (Upr)" , -3.53% (Lwr)	4mg (Upr), -3mg (Lwr)
93 - 100	96	4.00% (Upr)" , -3.23% (Lwr)	4mg (Upr), -3mg (Lwr)
101 - 108	104	3.70% (Upr)" , -2.97% (Lwr)	4mg (Upr), -3mg (Lwr)
109 - 116	112	3.45% (Upr)" , -2.75% (Lwr)	4mg (Upr), -3mg (Lwr)
117 - 126	120	4.76% (Upr)" , -2.56% (Lwr)	6mg (Upr), -3mg (Lwr)
127 - 138	132	4.35% (Upr)" , -3.94% (Lwr)	6mg (Upr), -5mg (Lwr)
139 - 150	144	4.00% (Upr)" , -3.60% (Lwr)	6mg (Upr), -5mg (Lwr)
151 - 162	156	3.70% (Upr)" , -3.31% (Lwr)	6mg (Upr), -5mg (Lwr)
163 - 174	168	3.45% (Upr)" , -3.07% (Lwr)	6mg (Upr), -5mg (Lwr)
175 - 189	180	4.76% (Upr)" , -2.86% (Lwr)	9mg (Upr), -5mg (Lwr)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	280	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	300	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	320	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	340	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	360	5.01% (Upr)" , -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 420	400	4.76% (Upr)" , -5.26% (Lwr)	20mg (Upr), -20mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

5-FLUOROURACIL IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 25mg/ml concentration of 5-fluorouracil.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
238 - 262	250	4.58% (Upr)" , -5.04% (Lwr)	12mg (Upr), -12mg (Lwr)
263 - 287	275	4.18% (Upr)" , -4.56% (Lwr)	12mg (Upr), -12mg (Lwr)
288 - 312	300	3.85% (Upr)" , -4.17% (Lwr)	12mg (Upr), -12mg (Lwr)
313 - 337	325	3.56% (Upr)" , -3.83% (Lwr)	12mg (Upr), -12mg (Lwr)
338 - 362	350	3.31% (Upr)" , -3.55% (Lwr)	12mg (Upr), -12mg (Lwr)
363 - 387	375	3.10% (Upr)" , -3.31% (Lwr)	12mg (Upr), -12mg (Lwr)
388 - 424	400	5.66% (Upr)" , -3.09% (Lwr)	24mg (Upr), -12mg (Lwr)
425 - 474	450	5.06% (Upr)" , -5.88% (Lwr)	24mg (Upr), -25mg (Lwr)
475 - 525	500	4.76% (Upr)" , -5.26% (Lwr)	25mg (Upr), -25mg (Lwr)
526 - 575	550	4.35% (Upr)" , -4.56% (Lwr)	25mg (Upr), -24mg (Lwr)
576 - 625	600	4.00% (Upr)" , -4.17% (Lwr)	25mg (Upr), -24mg (Lwr)
626 - 675	650	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)
676 - 725	700	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)
726 - 775	750	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)
776 - 825	800	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)
826 - 875	850	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)
876 - 925	900	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)
926 - 975	950	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)
976 - 1050	1000	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	1100	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	1300	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1450	1400	3.45% (Upr)" , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)
1451 - 1550	1500	3.23% (Upr)" , -3.38% (Lwr)	50mg (Upr), -49mg (Lwr)
1551 - 1650	1600	3.03% (Upr)" , -3.16% (Lwr)	50mg (Upr), -49mg (Lwr)
1651 - 1775	1700	4.23% (Upr)" , -2.97% (Lwr)	75mg (Upr), -49mg (Lwr)
1776 - 1925	1850	3.90% (Upr)" , -4.17% (Lwr)	75mg (Upr), -74mg (Lwr)
1926 - 2100	2000	4.76% (Upr)" , -3.84% (Lwr)	100mg (Upr), -74mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

5-FLUOROURACIL IV Infusion (Version 2) continued			
2101 - 2300	2200	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2500	2400	4.00% (Upr)" , -4.30% (Lwr)	100mg (Upr), -99mg (Lwr)
2501 - 2700	2600	3.70% (Upr)" , -3.96% (Lwr)	100mg (Upr), -99mg (Lwr)
2701 - 2900	2800	3.45% (Upr)" , -3.67% (Lwr)	100mg (Upr), -99mg (Lwr)
2901 - 3150	3000	4.76% (Upr)" , -3.41% (Lwr)	150mg (Upr), -99mg (Lwr)
3151 - 3450	3300	4.35% (Upr)" , -4.73% (Lwr)	150mg (Upr), -149mg (Lwr)
3451 - 3750	3600	4.00% (Upr)" , -4.32% (Lwr)	150mg (Upr), -149mg (Lwr)
3751 - 4050	3900	3.70% (Upr)" , -3.97% (Lwr)	150mg (Upr), -149mg (Lwr)
4051 - 4400	4200	4.55% (Upr)" , -3.68% (Lwr)	200mg (Upr), -149mg (Lwr)
4401 - 4800	4600	4.17% (Upr)" , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5200	5000	3.85% (Upr)" , -4.14% (Lwr)	200mg (Upr), -199mg (Lwr)
5201 - 5600	5400	3.57% (Upr)" , -3.83% (Lwr)	200mg (Upr), -199mg (Lwr)
5601 - 6100	5800	4.92% (Upr)" , -3.55% (Lwr)	300mg (Upr), -199mg (Lwr)
6101 - 6700	6400	4.48% (Upr)" , -4.90% (Lwr)	300mg (Upr), -299mg (Lwr)
6701 - 7300	7000	4.11% (Upr)" , -4.46% (Lwr)	300mg (Upr), -299mg (Lwr)
7301 - 8000	7600	5.00% (Upr)" , -4.10% (Lwr)	400mg (Upr), -299mg (Lwr)
8001 - 8800	8400	4.55% (Upr)" , -4.99% (Lwr)	400mg (Upr), -399mg (Lwr)
8801 - 9600	9200	4.17% (Upr)" , -4.53% (Lwr)	400mg (Upr), -399mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

5-FLUOROURACIL INFUSORS (Version 3)

The dose bands used in this table are constructed based on a 50mg/ml concentration of 5-fluorouracil.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
976 - 1050	1000	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	1100	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	1300	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1450	1400	3.45% (Upr)" , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)
1451 - 1550	1500	3.23% (Upr)" , -3.38% (Lwr)	50mg (Upr), -49mg (Lwr)
1551 - 1650	1600	3.03% (Upr)" , -3.16% (Lwr)	50mg (Upr), -49mg (Lwr)
1651 - 1775	1700	4.23% (Upr)" , -2.97% (Lwr)	75mg (Upr), -49mg (Lwr)
1776 - 1925	1850	3.90% (Upr)" , -4.17% (Lwr)	75mg (Upr), -74mg (Lwr)
1926 - 2100	2000	4.76% (Upr)" , -3.84% (Lwr)	100mg (Upr), -74mg (Lwr)
2101 - 2300	2200	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2500	2400	4.00% (Upr)" , -4.30% (Lwr)	100mg (Upr), -99mg (Lwr)
2501 - 2700	2600	3.70% (Upr)" , -3.96% (Lwr)	100mg (Upr), -99mg (Lwr)
2701 - 2900	2800	3.45% (Upr)" , -3.67% (Lwr)	100mg (Upr), -99mg (Lwr)
2901 - 3150	3000	4.76% (Upr)" , -3.41% (Lwr)	150mg (Upr), -99mg (Lwr)
3151 - 3450	3300	4.35% (Upr)" , -4.73% (Lwr)	150mg (Upr), -149mg (Lwr)
3451 - 3750	3600	4.00% (Upr)" , -4.32% (Lwr)	150mg (Upr), -149mg (Lwr)
3751 - 4050	3900	3.70% (Upr)" , -3.97% (Lwr)	150mg (Upr), -149mg (Lwr)
4051 - 4400	4200	4.55% (Upr)" , -3.68% (Lwr)	200mg (Upr), -149mg (Lwr)
4401 - 4800	4600	4.17% (Upr)" , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5200	5000	3.85% (Upr)" , -4.14% (Lwr)	200mg (Upr), -199mg (Lwr)
5201 - 5600	5400	3.57% (Upr)" , -3.83% (Lwr)	200mg (Upr), -199mg (Lwr)
5601 - 6100	5800/ 5750mg*	4.92% (Upr)" , -3.55% (Lwr)	300mg (Upr), -199mg (Lwr)
6101 - 6700	6400	4.48% (Upr)" , -4.90% (Lwr)	300mg (Upr), -299mg (Lwr)
6701 - 7300	7000	4.11% (Upr)" , -4.46% (Lwr)	300mg (Upr), -299mg (Lwr)
7301 - 8000	7600	5.00% (Upr)" , -4.10% (Lwr)	400mg (Upr), -299mg (Lwr)
8001 - 8800	8400	4.55% (Upr)" , -4.99% (Lwr)	400mg (Upr), -399mg (Lwr)
8801 - 9600	9200	4.17% (Upr)" , -4.53% (Lwr)	400mg (Upr), -399mg (Lwr)

*Please note that for SV 2.5 infusors, the banded dose to be used is 5750mg in order to accommodate the maximum fill volume of the SV2.5.

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

100mg/ml GEMCITABINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a **100mg/ml** concentration of gemcitabine. Alternative tables are supplied for gemcitabine 38mg/ml and gemcitabine 40mg/ml.

Please note that there are three tables for gemcitabine with different concentrations. Please ensure to use the dose bands applicable to the concentration used in your local site. This should be defined in your dose banding procedures. Please refer to Section 5.3 of the NCCP Dose Banding for SACT Guidance document (available [here](#)) for guidance in relation to dose banding for commercially available extended shelf-life ready to administer (RTA) products.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
530 - 589	560	4.92% (Upr)" , -5.66% (Lwr)	29mg (Upr), -30mg (Lwr)
590 - 649	620	4.47% (Upr)" , -5.08% (Lwr)	29mg (Upr), -30mg (Lwr)
650 - 709	680	4.09% (Upr)" , -4.62% (Lwr)	29mg (Upr), -30mg (Lwr)
710 - 759	740	2.50% (Upr)" , -4.23% (Lwr)	19mg (Upr), -30mg (Lwr)
760 - 849	800	5.77% (Upr)" , -5.26% (Lwr)	49mg (Upr), -40mg (Lwr)
850 - 949	900	5.16% (Upr)" , -5.88% (Lwr)	49mg (Upr), -50mg (Lwr)
950 - 1049	1000	4.67% (Upr)" , -5.26% (Lwr)	49mg (Upr), -50mg (Lwr)
1050 - 1149	1100	4.26% (Upr)" , -4.76% (Lwr)	49mg (Upr), -50mg (Lwr)
1150 - 1249	1200	3.92% (Upr)" , -4.35% (Lwr)	49mg (Upr), -50mg (Lwr)
1250 - 1349	1300	3.63% (Upr)" , -4.00% (Lwr)	49mg (Upr), -50mg (Lwr)
1350 - 1449	1400	3.38% (Upr)" , -3.70% (Lwr)	49mg (Upr), -50mg (Lwr)
1450 - 1549	1500	3.16% (Upr)" , -3.45% (Lwr)	49mg (Upr), -50mg (Lwr)
1550 - 1649	1600	2.97% (Upr)" , -3.23% (Lwr)	49mg (Upr), -50mg (Lwr)
1650 - 1749	1700	2.80% (Upr)" , -3.03% (Lwr)	49mg (Upr), -50mg (Lwr)
1750 - 1899	1800	5.21% (Upr)" , -2.86% (Lwr)	99mg (Upr), -50mg (Lwr)
1900 - 2099	2000	4.72% (Upr)" , -5.26% (Lwr)	99mg (Upr), -100mg (Lwr)
2100 - 2299	2200	4.31% (Upr)" , -4.76% (Lwr)	99mg (Upr), -100mg (Lwr)
2300 - 2499	2400	3.96% (Upr)" , -4.35% (Lwr)	99mg (Upr), -100mg (Lwr)
2500 - 2699	2600	3.67% (Upr)" , -4.00% (Lwr)	99mg (Upr), -100mg (Lwr)
2700 - 2899	2800	3.41% (Upr)" , -3.70% (Lwr)	99mg (Upr), -100mg (Lwr)
2900 - 3099	3000	3.19% (Upr)" , -3.45% (Lwr)	99mg (Upr), -100mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

40mg/ml GEMCITABINE IV INFUSION

(Version 4)

The dose bands used in this table are constructed based on a **40mg/ml** concentration of gemcitabine.

Alternative tables are supplied for gemcitabine 100mg/ml and gemcitabine 38mg/ml.

Please note that there are three tables for gemcitabine with different concentrations. Please ensure to use the dose bands applicable to the concentration used in your local site. This should be defined in your dose banding procedures.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
541 - 580	560	3.45% (Upr)" , -3.51% (Lwr)	20mg (Upr), -19mg (Lwr)
581 - 620	600	3.23% (Upr)" , -3.27% (Lwr)	20mg (Upr), -19mg (Lwr)
621 - 660	640	3.03% (Upr)" , -3.06% (Lwr)	20mg (Upr), -19mg (Lwr)
661 - 700	680	2.86% (Upr)" , -2.87% (Lwr)	20mg (Upr), -19mg (Lwr)
701 - 740	720	2.70% (Upr)" , -2.71% (Lwr)	20mg (Upr), -19mg (Lwr)
741 - 780	760	2.56% (Upr)" , -2.56% (Lwr)	20mg (Upr), -19mg (Lwr)
781 - 820	800	2.44% (Upr)" , -2.43% (Lwr)	20mg (Upr), -19mg (Lwr)
821 - 880	840	4.55% (Upr)" , -2.31% (Lwr)	40mg (Upr), -19mg (Lwr)
881 - 960	920	4.17% (Upr)" , -4.43% (Lwr)	40mg (Upr), -39mg (Lwr)
961 - 1040	1000	3.85% (Upr)" , -4.06% (Lwr)	40mg (Upr), -39mg (Lwr)
1041 - 1120	1080	3.57% (Upr)" , -3.75% (Lwr)	40mg (Upr), -39mg (Lwr)
1121 - 1200	1160	3.33% (Upr)" , -3.48% (Lwr)	40mg (Upr), -39mg (Lwr)
1201 - 1300	1240	4.62% (Upr)" , -3.25% (Lwr)	60mg (Upr), -39mg (Lwr)
1301 - 1420	1360	4.23% (Upr)" , -4.53% (Lwr)	60mg (Upr), -59mg (Lwr)
1421 - 1540	1480	3.90% (Upr)" , -4.15% (Lwr)	60mg (Upr), -59mg (Lwr)
1541 - 1660	1600	3.61% (Upr)" , -3.83% (Lwr)	60mg (Upr), -59mg (Lwr)
1661 - 1780	1720	3.37% (Upr)" , -3.55% (Lwr)	60mg (Upr), -59mg (Lwr)
1781 - 1920	1840	4.17% (Upr)" , -3.31% (Lwr)	80mg (Upr), -59mg (Lwr)
1921 - 2100	2000	4.76% (Upr)" , -4.11% (Lwr)	100mg (Upr), -79mg (Lwr)
2101 - 2300	2200	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2500	2400	4.00% (Upr)" , -4.30% (Lwr)	100mg (Upr), -99mg (Lwr)
2501 - 2700	2600	3.70% (Upr)" , -3.96% (Lwr)	100mg (Upr), -99mg (Lwr)
2701 - 2900	2800	3.45% (Upr)" , -3.67% (Lwr)	100mg (Upr), -99mg (Lwr)
2901 - 3100	3000	3.23% (Upr)" , -3.41% (Lwr)	100mg (Upr), -99mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

38mg/ml GEMCITABINE IV INFUSION (Version 4)

The dose bands used in this table are constructed based on a **38mg/ml** concentration of gemcitabine. Alternative tables are supplied for gemcitabine 100mg/ml and gemcitabine 40mg/ml.

Please note that there are three tables for gemcitabine with different concentrations. Please ensure to use the dose bands applicable to the concentration used in your local site. This should be defined in your dose banding procedures.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
550 - 589	570	3.23% (Upr)" , -3.64% (Lwr)	19mg (Upr), -20mg (Lwr)
590 - 627	608	3.03% (Upr)" , -3.05% (Lwr)	19mg (Upr), -18mg (Lwr)
628 - 665	646	2.86% (Upr)" , -2.87% (Lwr)	19mg (Upr), -18mg (Lwr)
666 - 703	684	2.70% (Upr)" , -2.70% (Lwr)	19mg (Upr), -18mg (Lwr)
704 - 759	722	4.87% (Upr)" , -2.56% (Lwr)	37mg (Upr), -18mg (Lwr)
760 - 835	798	4.43% (Upr)" , -5.00% (Lwr)	37mg (Upr), -38mg (Lwr)
836 - 912	874	4.17% (Upr)" , -4.55% (Lwr)	38mg (Upr), -38mg (Lwr)
913 - 988	950	3.85% (Upr)" , -4.05% (Lwr)	38mg (Upr), -37mg (Lwr)
989 - 1064	1026	3.57% (Upr)" , -3.74% (Lwr)	38mg (Upr), -37mg (Lwr)
1065 - 1139	1102	3.25% (Upr)" , -3.47% (Lwr)	37mg (Upr), -37mg (Lwr)
1140 - 1216	1178	3.13% (Upr)" , -3.33% (Lwr)	38mg (Upr), -38mg (Lwr)
1217 - 1292	1254	2.94% (Upr)" , -3.04% (Lwr)	38mg (Upr), -37mg (Lwr)
1293 - 1368	1330	2.78% (Upr)" , -2.86% (Lwr)	38mg (Upr), -37mg (Lwr)
1369 - 1520	1444	5.00% (Upr)" , -5.48% (Lwr)	76mg (Upr), -75mg (Lwr)
1521 - 1672	1596	4.55% (Upr)" , -4.93% (Lwr)	76mg (Upr), -75mg (Lwr)
1673 - 1824	1748	4.17% (Upr)" , -4.48% (Lwr)	76mg (Upr), -75mg (Lwr)
1825 - 1995	1900	4.76% (Upr)" , -4.11% (Lwr)	95mg (Upr), -75mg (Lwr)
1996 - 2166	2090	3.51% (Upr)" , -4.71% (Lwr)	76mg (Upr), -94mg (Lwr)
2167 - 2375	2280	4.00% (Upr)" , -5.21% (Lwr)	95mg (Upr), -113mg (Lwr)
2376 - 2565	2470	3.70% (Upr)" , -3.96% (Lwr)	95mg (Upr), -94mg (Lwr)
2566 - 2755	2660	3.45% (Upr)" , -3.66% (Lwr)	95mg (Upr), -94mg (Lwr)
2756 - 2945	2850	3.23% (Upr)" , -3.41% (Lwr)	95mg (Upr), -94mg (Lwr)
2946 - 3150	3040	3.49% (Upr)" , -3.19% (Lwr)	110mg (Upr), -94mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

IFOSFAMIDE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on an 80mg/ml concentration of ifosfamide.

Dose Range (mg)	Banded dose (mg)	Maximum variation range	Maximum variation range
911 - 990	960	3.03% (Upr)" , -5.38% (Lwr)	30mg (Upr), -49mg (Lwr)
991 - 1080	1040	3.70% (Upr)" , -4.94% (Lwr)	40mg (Upr), -49mg (Lwr)
1081 - 1160	1120	3.45% (Upr)" , -3.61% (Lwr)	40mg (Upr), -39mg (Lwr)
1161 - 1240	1200	3.23% (Upr)" , -3.36% (Lwr)	40mg (Upr), -39mg (Lwr)
1241 - 1320	1280	3.03% (Upr)" , -3.14% (Lwr)	40mg (Upr), -39mg (Lwr)
1321 - 1400	1360	2.86% (Upr)" , -2.95% (Lwr)	40mg (Upr), -39mg (Lwr)
1401 - 1520	1440	5.26% (Upr)" , -2.78% (Lwr)	80mg (Upr), -39mg (Lwr)
1521 - 1680	1600	4.76% (Upr)" , -5.19% (Lwr)	80mg (Upr), -79mg (Lwr)
1681 - 1840	1760	4.35% (Upr)" , -4.70% (Lwr)	80mg (Upr), -79mg (Lwr)
1841 - 2000	1920	4.00% (Upr)" , -4.29% (Lwr)	80mg (Upr), -79mg (Lwr)
2001 - 2160	2080	3.70% (Upr)" , -3.95% (Lwr)	80mg (Upr), -79mg (Lwr)
2161 - 2300	2240	2.61% (Upr)" , -3.66% (Lwr)	60mg (Upr), -79mg (Lwr)
2301 - 2520	2400	4.76% (Upr)" , -4.30% (Lwr)	120mg (Upr), -99mg (Lwr)
2521 - 2760	2640	4.35% (Upr)" , -4.72% (Lwr)	120mg (Upr), -119mg (Lwr)
2761 - 3000	2880	4.00% (Upr)" , -4.31% (Lwr)	120mg (Upr), -119mg (Lwr)
3001 - 3240	3120	3.70% (Upr)" , -3.97% (Lwr)	120mg (Upr), -119mg (Lwr)
3241 - 3520	3360	4.55% (Upr)" , -3.67% (Lwr)	160mg (Upr), -119mg (Lwr)
3521 - 3840	3680	4.17% (Upr)" , -4.52% (Lwr)	160mg (Upr), -159mg (Lwr)
3841 - 4160	4000	3.85% (Upr)" , -4.14% (Lwr)	160mg (Upr), -159mg (Lwr)
4161 - 4480	4320	3.57% (Upr)" , -3.82% (Lwr)	160mg (Upr), -159mg (Lwr)
4481 - 4880	4640	4.92% (Upr)" , -3.55% (Lwr)	240mg (Upr), -159mg (Lwr)
4881 - 5360	5120	4.48% (Upr)" , -4.90% (Lwr)	240mg (Upr), -239mg (Lwr)
5361 - 5840	5600	4.11% (Upr)" , -4.46% (Lwr)	240mg (Upr), -239mg (Lwr)
5841 - 6400	6080	5.00% (Upr)" , -4.09% (Lwr)	320mg (Upr), -239mg (Lwr)
6401 - 7040	6720	4.55% (Upr)" , -4.98% (Lwr)	320mg (Upr), -319mg (Lwr)
7041 - 7680	7360	4.17% (Upr)" , -4.53% (Lwr)	320mg (Upr), -319mg (Lwr)
7681 - 8400	8000	4.76% (Upr)" , -4.15% (Lwr)	400mg (Upr), -319mg (Lwr)
8401 - 9280	8800	5.17% (Upr)" , -4.75% (Lwr)	480mg (Upr), -399mg (Lwr)
9281 - 10240	9760	4.69% (Upr)" , -5.16% (Lwr)	480mg (Upr), -479mg (Lwr)
10241 - 11200	10720	4.29% (Upr)" , -4.68% (Lwr)	480mg (Upr), -479mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

IFOSFAMIDE IV Infusion (Version 1) continued			
11201 - 12160	11680	3.95% (Upr)", -4.28% (Lwr)	480mg (Upr), -479mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

IRINOTECAN IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 20mg/ml concentration of irinotecan.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Please refer to Section 5.3 of the NCCP Dose Banding for SACT Guidance document (available [here](#)) for guidance in relation to dose banding for commercially available extended shelf-life ready to administer (RTA) products.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
190 - 209	200	4.31% (Upr)" -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	280	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	300	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	320	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	340	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	360	5.01% (Upr)" , -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 419	400	4.53% (Upr)" , -5.26% (Lwr)	19mg (Upr), -20mg (Lwr)
420 - 459	440	4.14% (Upr)" , -4.76% (Lwr)	19mg (Upr), -20mg (Lwr)
460 - 499	480	3.81% (Upr)" , -4.35% (Lwr)	19mg (Upr), -20mg (Lwr)
500 - 539	520	3.53% (Upr)" , -4.00% (Lwr)	19mg (Upr), -20mg (Lwr)
540 - 579	560	3.28% (Upr)" , -3.70% (Lwr)	19mg (Upr), -20mg (Lwr)
580 - 619	600	3.07% (Upr)" , -3.45% (Lwr)	19mg (Upr), -20mg (Lwr)
620 - 659	640	2.88% (Upr)" , -3.23% (Lwr)	19mg (Upr), -20mg (Lwr)
660 - 709	680	4.09% (Upr)" , -3.03% (Lwr)	29mg (Upr), -20mg (Lwr)
710 - 769	740	3.77% (Upr)" , -4.23% (Lwr)	29mg (Upr), -30mg (Lwr)
770 - 830	800	3.61% (Upr)" , -3.90% (Lwr)	30mg (Upr), -30mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

METHOTREXATE IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 100mg/ml concentration of methotrexate.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
46 - 50	48	4.00% (Upr)" , -4.35% (Lwr)	2mg (Upr), -2mg (Lwr)
51 - 56	54	3.57% (Upr)" , -5.88% (Lwr)	2mg (Upr), -3mg (Lwr)
57 - 62	60	3.23% (Upr)" , -5.26% (Lwr)	2mg (Upr), -3mg (Lwr)
63 - 68	66	2.94% (Upr)" , -4.76% (Lwr)	2mg (Upr), -3mg (Lwr)
69 - 75	72	4.00% (Upr)" , -4.35% (Lwr)	3mg (Upr), -3mg (Lwr)
76 - 84	80	4.76% (Upr)" , -5.26% (Lwr)	4mg (Upr), -4mg (Lwr)
85 - 94	90	4.26% (Upr)" , -5.88% (Lwr)	4mg (Upr), -5mg (Lwr)
95 - 104	100	3.85% (Upr)" , -5.26% (Lwr)	4mg (Upr), -5mg (Lwr)
105 - 114	110	3.51% (Upr)" , -4.76% (Lwr)	4mg (Upr), -5mg (Lwr)
115 - 124	120	3.23% (Upr)" , -4.35% (Lwr)	4mg (Upr), -5mg (Lwr)
125 - 134	130	2.99% (Upr)" , -4.00% (Lwr)	4mg (Upr), -5mg (Lwr)
135 - 144	140	2.78% (Upr)" , -3.70% (Lwr)	4mg (Upr), -5mg (Lwr)
145 - 154	150	2.60% (Upr)" , -3.45% (Lwr)	4mg (Upr), -5mg (Lwr)
155 - 169	160	5.33% (Upr)" , -3.23% (Lwr)	9mg (Upr), -5mg (Lwr)
170 - 189	180	4.76% (Upr)" , -5.88% (Lwr)	9mg (Upr), -10mg (Lwr)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	280	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	300	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	320	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	340	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	360	5.01% (Upr)" , -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 419	400	4.53% (Upr)" , -5.26% (Lwr)	19mg (Upr), -20mg (Lwr)
420 - 459	440	4.14% (Upr)" , -4.76% (Lwr)	19mg (Upr), -20mg (Lwr)
460 - 499	480	3.81% (Upr)" , -4.35% (Lwr)	19mg (Upr), -20mg (Lwr)
500 - 539	520	3.53% (Upr)" , -4.00% (Lwr)	19mg (Upr), -20mg (Lwr)
540 - 579	560	3.28% (Upr)" , -3.70% (Lwr)	19mg (Upr), -20mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

METHOTREXATE IV INFUSION (Version 2) continued			
580 - 625	600	4.00% (Upr)" , -3.45% (Lwr)	25mg (Upr), -20mg (Lwr)
626 - 675	650	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)
676 - 725	700	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)
726 - 775	750	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)
776 - 825	800	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)
826 - 875	850	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)
876 - 925	900	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)
926 - 975	950	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)
976 - 1050	1000	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	1100	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	1300	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1450	1400	3.45% (Upr)" , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)
1451 - 1600	1500	6.25% (Upr)" , -3.38% (Lwr)	100mg (Upr), -49mg (Lwr)
1601 - 1750	1700	2.86% (Upr)" , -6.18% (Lwr)	50mg (Upr), -99mg (Lwr)
1751 - 1900	1800	5.26% (Upr)" , -2.80% (Lwr)	100mg (Upr), -49mg (Lwr)
1901 - 2100	2000	4.76% (Upr)" , -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)
2101 - 2300	2200	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2500	2400	4.00% (Upr)" , -4.30% (Lwr)	100mg (Upr), -99mg (Lwr)
2501 - 2750	2600	5.45% (Upr)" , -3.96% (Lwr)	150mg (Upr), -99mg (Lwr)
2751 - 3040	2900	4.61% (Upr)" , -5.42% (Lwr)	140mg (Upr), -149mg (Lwr)
3041 - 3350	3200	4.48% (Upr)" , -5.23% (Lwr)	150mg (Upr), -159mg (Lwr)
3351 - 3650	3500	4.11% (Upr)" , -4.45% (Lwr)	150mg (Upr), -149mg (Lwr)
3651 - 3990	3800	4.76% (Upr)" , -4.08% (Lwr)	190mg (Upr), -149mg (Lwr)
3991 - 4400	4200	4.55% (Upr)" , -5.24% (Lwr)	200mg (Upr), -209mg (Lwr)
4401 - 4800	4600	4.17% (Upr)" , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5250	5000	4.76% (Upr)" , -4.14% (Lwr)	250mg (Upr), -199mg (Lwr)
5251 - 5750	5500	4.35% (Upr)" , -4.74% (Lwr)	250mg (Upr), -249mg (Lwr)
5751 - 6250	6000	4.00% (Upr)" , -4.33% (Lwr)	250mg (Upr), -249mg (Lwr)
6251 - 6750	6500	3.70% (Upr)" , -3.98% (Lwr)	250mg (Upr), -249mg (Lwr)
6751 - 7250	7000	3.45% (Upr)" , -3.69% (Lwr)	250mg (Upr), -249mg (Lwr)
7251 - 7750	7500	3.23% (Upr)" , -3.43% (Lwr)	250mg (Upr), -249mg (Lwr)
7751 - 8250	8000	3.03% (Upr)" , -3.21% (Lwr)	250mg (Upr), -249mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

METHOTREXATE IV INFUSION (Version 2) continued			
8251 - 8750	8500	2.86% (Upr)" , -3.02% (Lwr)	250mg (Upr), -249mg (Lwr)
8751 - 9250	9000	2.70% (Upr)" , -2.85% (Lwr)	250mg (Upr), -249mg (Lwr)
9251 - 9750	9500	2.56% (Upr)" , -2.69% (Lwr)	250mg (Upr), -249mg (Lwr)
9751 - 10500	10000	4.76% (Upr)" , -2.55% (Lwr)	500mg (Upr), -249mg (Lwr)
10501 - 11500	11000	4.35% (Upr)" , -4.75% (Lwr)	500mg (Upr), -499mg (Lwr)
11501 - 12500	12000	4.00% (Upr)" , -4.34% (Lwr)	500mg (Upr), -499mg (Lwr)
12501 - 13500	13000	3.70% (Upr)" , -3.99% (Lwr)	500mg (Upr), -499mg (Lwr)
13501 - 14500	14000	3.45% (Upr)" , -3.70% (Lwr)	500mg (Upr), -499mg (Lwr)
14501 - 15500	15000	3.23% (Upr)" , -3.44% (Lwr)	500mg (Upr), -499mg (Lwr)
15501 - 16500	16000	3.03% (Upr)" , -3.22% (Lwr)	500mg (Upr), -499mg (Lwr)
16501 - 17500	17000	2.86% (Upr)" , -3.02% (Lwr)	500mg (Upr), -499mg (Lwr)
17501 - 18500	18000	2.70% (Upr)" , -2.85% (Lwr)	500mg (Upr), -499mg (Lwr)
18501 - 19500	19000	2.56% (Upr)" , -2.70% (Lwr)	500mg (Upr), -499mg (Lwr)
19501 - 21000	20000	4.76% (Upr)" , -2.56% (Lwr)	1000mg (Upr), -499mg (Lwr)
21001 - 23000	22000	4.35% (Upr)" , -4.76% (Lwr)	1000mg (Upr), -999mg (Lwr)
23001 - 25000	24000	4.00% (Upr)" , -4.34% (Lwr)	1000mg (Upr), -999mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

NAB-PACLITAXEL IV INFUSION (Version 1.1)

The dose bands used in this table are constructed based on a 5mg/ml concentration of Nab-PACLitaxel.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
116 - 125	120	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	130	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	140	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 155	150	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)
156 - 165	160	3.03% (Upr)" , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)
166 - 176	170	3.41% (Upr)" , -2.41% (Lwr)	6mg (Upr), -4mg (Lwr)
177 - 191	185	3.14% (Upr)" , -4.52% (Lwr)	6mg (Upr), -8mg (Lwr)
192 - 210	200	4.76% (Upr)" , -4.17% (Lwr)	10mg (Upr), -8mg (Lwr)
211 - 230	220	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)
231 - 250	240	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)
251 - 270	260	3.70% (Upr)" , -3.59% (Lwr)	10mg (Upr), -9mg (Lwr)
271 - 290	280	3.45% (Upr)" , -3.32% (Lwr)	10mg (Upr), -9mg (Lwr)
291 - 315	300	4.76% (Upr)" , -3.09% (Lwr)	15mg (Upr), -9mg (Lwr)
316 - 340	325	4.41% (Upr)" , -2.85% (Lwr)	15mg (Upr), -9mg (Lwr)
341 - 365	350	4.11% (Upr)" , -2.64% (Lwr)	15mg (Upr), -9mg (Lwr)
366 - 390	375	3.85% (Upr)" , -2.46% (Lwr)	15mg (Upr), -9mg (Lwr)
391 - 420	400	4.76% (Upr)" , -2.30% (Lwr)	20mg (Upr), -9mg (Lwr)
421 - 460	440	4.35% (Upr)" , -4.51% (Lwr)	20mg (Upr), -19mg (Lwr)
461 - 500	480	4.00% (Upr)" , -4.12% (Lwr)	20mg (Upr), -19mg (Lwr)
501 - 540	520	3.70% (Upr)" , -3.79% (Lwr)	20mg (Upr), -19mg (Lwr)
541 - 580	560	3.45% (Upr)" , -3.51% (Lwr)	20mg (Upr), -19mg (Lwr)
581 - 620	600	3.23% (Upr)" , -3.27% (Lwr)	20mg (Upr), -19mg (Lwr)
621 - 660	640	3.03% (Upr)" , -3.06% (Lwr)	20mg (Upr), -19mg (Lwr)
661 - 700	680	2.86% (Upr)" , -2.87% (Lwr)	20mg (Upr), -19mg (Lwr)
701 - 740	720	2.70% (Upr)" , -2.71% (Lwr)	20mg (Upr), -19mg (Lwr)
741 - 780	760	2.56% (Upr)" , -2.56% (Lwr)	20mg (Upr), -19mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

OXALIPLATIN IV INFUSION (Version 3)

The dose bands used in this table are constructed based on a 5mg/ml concentration of oxaliplatin.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
58 - 62	60	3.23% (Upr)" , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)
63 - 67	65	2.99% (Upr)" , -3.17% (Lwr)	2mg (Upr), -2mg (Lwr)
68 - 72	70	2.78% (Upr)" , -2.94% (Lwr)	2mg (Upr), -2mg (Lwr)
73 - 77	75	2.60% (Upr)" , -2.74% (Lwr)	2mg (Upr), -2mg (Lwr)
78 - 84	80	4.76% (Upr)" , -2.56% (Lwr)	4mg (Upr), -2mg (Lwr)
85 - 94	90	4.26% (Upr)" , -5.88% (Lwr)	4mg (Upr), -5mg (Lwr)
95 - 105	100	4.76% (Upr)" , -5.26% (Lwr)	5mg (Upr), -5mg (Lwr)
106 - 115	110	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)
116 - 125	120	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	130	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	140	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 155	150	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)
156 - 165	160	3.03% (Upr)" , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)
166 - 175	170	2.86% (Upr)" , -2.41% (Lwr)	5mg (Upr), -4mg (Lwr)
176 - 190	185	2.63% (Upr)" , -5.11% (Lwr)	5mg (Upr), -9mg (Lwr)
191 - 210	200	4.76% (Upr)" , -4.71% (Lwr)	10mg (Upr), -9mg (Lwr)
211 - 230	220	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)
231 - 250	240	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)
251 - 270	260	3.70% (Upr)" , -3.59% (Lwr)	10mg (Upr), -9mg (Lwr)
271 - 290	280	3.45% (Upr)" , -3.32% (Lwr)	10mg (Upr), -9mg (Lwr)
291 - 310	300	3.23% (Upr)" , -3.09% (Lwr)	10mg (Upr), -9mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

PACLITAXEL IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 6mg/ml concentration of PACLitaxel.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
57 - 63	60	4.76% (Upr)" -5.26% (Lwr)	3mg (Upr), -3mg (Lwr)
64 - 69	66	4.35% (Upr)" , -3.13% (Lwr)	3mg (Upr), -2mg (Lwr)
70 - 75	72	4.00% (Upr)" , -2.86% (Lwr)	3mg (Upr), -2mg (Lwr)
76 - 81	78	3.70% (Upr)" , -2.63% (Lwr)	3mg (Upr), -2mg (Lwr)
82 - 86	84	2.33% (Upr)" , -2.44% (Lwr)	2mg (Upr), -2mg (Lwr)
87 - 93	90	3.23% (Upr)" , -3.45% (Lwr)	3mg (Upr), -3mg (Lwr)
94 - 99	96	3.03% (Upr)" , -2.13% (Lwr)	3mg (Upr), -2mg (Lwr)
100 - 105	102	2.86% (Upr)" , -2.00% (Lwr)	3mg (Upr), -2mg (Lwr)
106 - 113	108	4.42% (Upr)" , -1.89% (Lwr)	5mg (Upr), -2mg (Lwr)
114 - 126	120	4.76% (Upr)" , -5.26% (Lwr)	6mg (Upr), -6mg (Lwr)
127 - 138	132	4.35% (Upr)" , -3.94% (Lwr)	6mg (Upr), -5mg (Lwr)
139 - 150	144	4.00% (Upr)" , -3.60% (Lwr)	6mg (Upr), -5mg (Lwr)
151 - 162	156	3.70% (Upr)" , -3.31% (Lwr)	6mg (Upr), -5mg (Lwr)
163 - 174	168	3.45% (Upr)" , -3.07% (Lwr)	6mg (Upr), -5mg (Lwr)
175 - 186	180	3.23% (Upr)" , -2.86% (Lwr)	6mg (Upr), -5mg (Lwr)
187 - 198	192	3.03% (Upr)" , -2.67% (Lwr)	6mg (Upr), -5mg (Lwr)
199 - 210	204	2.86% (Upr)" , -2.51% (Lwr)	6mg (Upr), -5mg (Lwr)
211 - 222	216	2.70% (Upr)" , -2.37% (Lwr)	6mg (Upr), -5mg (Lwr)
223 - 246	234	4.88% (Upr)" , -4.93% (Lwr)	12mg (Upr), -11mg (Lwr)
247 - 264	252	4.55% (Upr)" , -2.02% (Lwr)	12mg (Upr), -5mg (Lwr)
265 - 282	270	4.26% (Upr)" , -1.89% (Lwr)	12mg (Upr), -5mg (Lwr)
283 - 306	294	3.92% (Upr)" , -3.89% (Lwr)	12mg (Upr), -11mg (Lwr)
307 - 330	318	3.64% (Upr)" , -3.58% (Lwr)	12mg (Upr), -11mg (Lwr)
331 - 354	342	3.39% (Upr)" , -3.32% (Lwr)	12mg (Upr), -11mg (Lwr)
355 - 378	366	3.17% (Upr)" , -3.10% (Lwr)	12mg (Upr), -11mg (Lwr)
379 - 402	390	2.99% (Upr)" , -2.90% (Lwr)	12mg (Upr), -11mg (Lwr)
403 - 426	414	2.82% (Upr)" , -2.73% (Lwr)	12mg (Upr), -11mg (Lwr)
427 - 450	438	2.67% (Upr)" , -2.58% (Lwr)	12mg (Upr), -11mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

PEMETREXED IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 25mg/ml concentration of PEMEtrexed.

Please refer to Section 5.3 of the NCCP Dose Banding for SACT Guidance document (available [here](#)) for guidance in relation to dose banding for commercially available extended shelf-life ready to administer (RTA) products.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
475-524	500	4.58% (Upr)" , -5.26% (Lwr)	24mg (Upr), -25mg (Lwr)
525-574	550	4.18% (Upr)" , -4.76% (Lwr)	24mg (Upr), -25mg (Lwr)
575-624	600	3.85% (Upr)" , -4.35% (Lwr)	24mg (Upr), -25mg (Lwr)
625-674	650	3.56% (Upr)" , -4.00% (Lwr)	24mg (Upr), -25mg (Lwr)
675-724	700	3.31% (Upr)" , -3.70% (Lwr)	24mg (Upr), -25mg (Lwr)
725-785	750	4.46% (Upr)" , -3.45% (Lwr)	35mg (Upr), -25mg (Lwr)
786-859	825	3.96% (Upr)" , -4.96% (Lwr)	34mg (Upr), -39mg (Lwr)
860-949	900	5.16% (Upr)" , -4.65% (Lwr)	49mg (Upr), -40mg (Lwr)
950-1049	1000	4.67% (Upr)" , -5.26% (Lwr)	49mg (Upr), -50mg (Lwr)
1050-1149	1100	4.26% (Upr)" , -4.76% (Lwr)	49mg (Upr), -50mg (Lwr)
1150-1249	1200	3.92% (Upr)" , -4.35% (Lwr)	49mg (Upr), -50mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

TOPOTECAN IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 1mg/ml concentration of topotecan.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
0.96 - 1.04	1	3.85% (Upr)" , -4.17% (Lwr)	0.04mg (Upr), -0.04mg (Lwr)
1.05 - 1.14	1.1	3.51% (Upr)" , -4.76% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.15 - 1.24	1.2	3.23% (Upr)" , -4.35% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.25 - 1.34	1.3	2.99% (Upr)" , -4.00% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.35 - 1.44	1.4	2.78% (Upr)" , -3.70% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.45 - 1.54	1.5	2.60% (Upr)" , -3.45% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.55 - 1.64	1.6	2.44% (Upr)" , -3.23% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.65 - 1.74	1.7	2.30% (Upr)" , -3.03% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.75 - 1.89	1.8	4.76% (Upr)" , -2.86% (Lwr)	0.09mg (Upr), -0.05mg (Lwr)
1.9 - 2.09	2	4.31% (Upr)" , -5.26% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
2.1 - 2.29	2.2	3.93% (Upr)" , -4.76% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
2.3 - 2.49	2.4	3.61% (Upr)" , -4.35% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
2.5 - 2.69	2.6	3.35% (Upr)" , -4.00% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
2.7 - 2.89	2.8	3.11% (Upr)" , -3.70% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
2.9 - 3.09	3	2.91% (Upr)" , -3.45% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
3.1 - 3.29	3.2	2.74% (Upr)" , -3.23% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
3.3 - 3.49	3.4	2.58% (Upr)" , -3.03% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
3.5 - 3.69	3.6	2.44% (Upr)" , -2.86% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
3.7 - 3.89	3.8	2.31% (Upr)" , -2.70% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
3.9 - 4.19	4	4.53% (Upr)" , -2.56% (Lwr)	0.19mg (Upr), -0.10mg (Lwr)
4.2 - 4.59	4.4	4.14% (Upr)" , -4.76% (Lwr)	0.19mg (Upr), -0.20mg (Lwr)
4.6 - 4.99	4.8	3.81% (Upr)" , -4.35% (Lwr)	0.19mg (Upr), -0.20mg (Lwr)
5 - 5.39	5.2	3.53% (Upr)" , -4.00% (Lwr)	0.19mg (Upr), -0.20mg (Lwr)
5.4 - 5.89	5.6	4.92% (Upr)" , -3.70% (Lwr)	0.29mg (Upr), -0.20mg (Lwr)
5.9 - 6.49	6.2	4.47% (Upr)" , -5.08% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
6.5 - 7.09	6.8	4.09% (Upr)" , -4.62% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
7.1 - 7.79	7.4	5.01% (Upr)" , -4.23% (Lwr)	0.39mg (Upr), -0.30mg (Lwr)
7.8 - 8.39	8	4.65% (Upr)" , -2.56% (Lwr)	0.39mg (Upr), -0.20mg (Lwr)
8.4 - 9.09	8.8	3.19% (Upr)" , -4.76% (Lwr)	0.29mg (Upr), -0.40mg (Lwr)
9.1 - 9.89	9.4	4.95% (Upr)" , -3.30% (Lwr)	0.49mg (Upr), -0.30mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

TRASTUZUMAB EMTANSINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 20mg/ml concentration of trastuzumab emtansine. Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
65 - 72	68	5.56% (Upr)" , -4.62% (Lwr)	4mg (Upr), -3mg (Lwr)
73 - 80	76	5.00% (Upr)" , -4.11% (Lwr)	4mg (Upr), -3mg (Lwr)
81 - 88	84	4.55% (Upr)" , -3.70% (Lwr)	4mg (Upr), -3mg (Lwr)
89 - 96	92	4.17% (Upr)" , -3.37% (Lwr)	4mg (Upr), -3mg (Lwr)
97 - 104	100	3.85% (Upr)" , -3.09% (Lwr)	4mg (Upr), -3mg (Lwr)
105 - 114	108	5.26% (Upr)" , -2.86% (Lwr)	6mg (Upr), -3mg (Lwr)
115 - 126	120	4.76% (Upr)" , -4.35% (Lwr)	6mg (Upr), -5mg (Lwr)
127 - 138	132	4.35% (Upr)" , -3.94% (Lwr)	6mg (Upr), -5mg (Lwr)
139 - 150	144	4.00% (Upr)" , -3.60% (Lwr)	6mg (Upr), -5mg (Lwr)
151 - 162	156	3.70% (Upr)" , -3.31% (Lwr)	6mg (Upr), -5mg (Lwr)
163 - 174	168	3.45% (Upr)" , -3.07% (Lwr)	6mg (Upr), -5mg (Lwr)
175 - 189	180	4.76% (Upr)" , -2.86% (Lwr)	9mg (Upr), -5mg (Lwr)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	280	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	300	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	320	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	340	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	360	5.01% (Upr)" , -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 419	400	4.53% (Upr)" , -5.26% (Lwr)	19mg (Upr), -20mg (Lwr)
420 - 459	440	4.14% (Upr)" , -4.76% (Lwr)	19mg (Upr), -20mg (Lwr)
460 - 499	480	3.81% (Upr)" , -4.35% (Lwr)	19mg (Upr), -20mg (Lwr)
500 - 539	520	3.53% (Upr)" , -4.00% (Lwr)	19mg (Upr), -20mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

VINBLASTINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 1mg/ml concentration of vinblastine.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
2.7 - 2.89	2.8	3.11% (Upr)" , -3.70% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
2.9 - 3.09	3	2.91% (Upr)" , -3.45% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
3.1 - 3.29	3.2	2.74% (Upr)" , -3.23% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
3.3 - 3.59	3.4	5.29% (Upr)" , -3.03% (Lwr)	0.19mg (Upr), -0.10mg (Lwr)
3.6 - 3.99	3.8	4.76% (Upr)" , -5.56% (Lwr)	0.19mg (Upr), -0.20mg (Lwr)
4 - 4.39	4.2	4.33% (Upr)" , -5.00% (Lwr)	0.19mg (Upr), -0.20mg (Lwr)
4.4 - 4.79	4.6	3.97% (Upr)" , -4.55% (Lwr)	0.19mg (Upr), -0.20mg (Lwr)
4.8 - 5.29	5	5.48% (Upr)" , -4.17% (Lwr)	0.29mg (Upr), -0.20mg (Lwr)
5.3 - 5.89	5.6	4.92% (Upr)" , -5.66% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
5.9 - 6.49	6.2	4.47% (Upr)" , -5.08% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
6.5 - 7.19	6.8	5.42% (Upr)" , -4.62% (Lwr)	0.39mg (Upr), -0.30mg (Lwr)
7.2 - 7.99	7.6	4.88% (Upr)" , -5.56% (Lwr)	0.39mg (Upr), -0.40mg (Lwr)
8 - 8.79	8.4	4.44% (Upr)" , -5.00% (Lwr)	0.39mg (Upr), -0.40mg (Lwr)
8.8 - 9.59	9.2	4.07% (Upr)" , -4.55% (Lwr)	0.39mg (Upr), -0.40mg (Lwr)
9.6 - 10.49	10	4.67% (Upr)" , -4.17% (Lwr)	0.49mg (Upr), -0.40mg (Lwr)
10.5 - 11.49	11	4.26% (Upr)" , -4.76% (Lwr)	0.49mg (Upr), -0.50mg (Lwr)
11.5 - 12.49	12	3.92% (Upr)" , -4.35% (Lwr)	0.49mg (Upr), -0.50mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

VINCRIStINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 1mg/ml concentration of vinblastine.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
0.95 - 1.04	1	3.85% (Upr)" , -5.26% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.05 - 1.14	1.1	3.51% (Upr)" , -4.76% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.15 - 1.24	1.2	3.23% (Upr)" , -4.35% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.25 - 1.34	1.3	2.99% (Upr)" , -4.00% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.35 - 1.44	1.4	2.78% (Upr)" , -3.70% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.45 - 1.54	1.5	2.60% (Upr)" , -3.45% (Lwr)	0.04mg (Upr), -0.05mg (Lwr)
1.55 - 1.69	1.6	5.33% (Upr)" , -3.23% (Lwr)	0.09mg (Upr), -0.05mg (Lwr)
1.7 - 1.89	1.8	4.76% (Upr)" , -5.88% (Lwr)	0.09mg (Upr), -0.10mg (Lwr)
1.9 - 2.1	2	4.76% (Upr)" , -5.26% (Lwr)	0.10mg (Upr), -0.10mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

VINOURELBINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 10mg/ml concentration of vinorelbine.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
19 - 21	20	4.76% (Upr)" , -5.26% (Lwr)	1mg (Upr), -1mg (Lwr)
21.1 - 23	22	4.35% (Upr)" , -4.27% (Lwr)	1mg (Upr), -0.9mg (Lwr)
23.1 - 25	24	4.00% (Upr)" , -3.90% (Lwr)	1mg (Upr), -0.9mg (Lwr)
25.1 - 27	26	3.70% (Upr)" , -3.59% (Lwr)	1mg (Upr), -0.9mg (Lwr)
27.1 - 29	28	3.45% (Upr)" , -3.32% (Lwr)	1mg (Upr), -0.9mg (Lwr)
29.1 - 32	30	6.25% (Upr)" , -3.09% (Lwr)	2mg (Upr), -0.9mg (Lwr)
33 - 36	34	5.56% (Upr)" , -3.03% (Lwr)	2mg (Upr), -1mg (Lwr)
37 - 40	38	5.00% (Upr)" , -2.70% (Lwr)	2mg (Upr), -1mg (Lwr)
41 - 44	42	4.55% (Upr)" , -2.44% (Lwr)	2mg (Upr), -1mg (Lwr)
45 - 48	46	4.17% (Upr)" , -2.22% (Lwr)	2mg (Upr), -1mg (Lwr)
49 - 51	50	1.96% (Upr)" , -2.04% (Lwr)	1mg (Upr), -1mg (Lwr)
52 - 57	54	5.26% (Upr)" , -3.85% (Lwr)	3mg (Upr), -2mg (Lwr)
58 - 63	60	4.76% (Upr)" , -3.45% (Lwr)	3mg (Upr), -2mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOSE BANDING TABLES – MONOCLONALS FOR INTRAVENOUS INFUSION

MONOCLONALS - BEVACIZUMAB IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 25mg/ml concentration of bevacizumab.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
190 - 211	200	5.21% (Upr)" , -5.26% (Lwr)	11mg (Upr), -10mg (Lwr)
212 - 236	225	4.66% (Upr)" , -6.13% (Lwr)	11mg (Upr), -13mg (Lwr)
237 - 261	250	4.21% (Upr)" , -5.49% (Lwr)	11mg (Upr), -13mg (Lwr)
262 - 286	275	3.85% (Upr)" , -4.96% (Lwr)	11mg (Upr), -13mg (Lwr)
287 - 311	300	3.54% (Upr)" , -4.53% (Lwr)	11mg (Upr), -13mg (Lwr)
312 - 336	325	3.27% (Upr)" , -4.17% (Lwr)	11mg (Upr), -13mg (Lwr)
337 - 361	350	3.05% (Upr)" , -3.86% (Lwr)	11mg (Upr), -13mg (Lwr)
362 - 386	375	2.85% (Upr)" , -3.59% (Lwr)	11mg (Upr), -13mg (Lwr)
387 - 411	400	2.68% (Upr)" , -3.36% (Lwr)	11mg (Upr), -13mg (Lwr)
412 - 436	425	2.52% (Upr)" , -3.16% (Lwr)	11mg (Upr), -13mg (Lwr)
437 - 461	450	2.39% (Upr)" , -2.97% (Lwr)	11mg (Upr), -13mg (Lwr)
462 - 486	475	2.26% (Upr)" , -2.81% (Lwr)	11mg (Upr), -13mg (Lwr)
487 - 525	500	4.76% (Upr)" , -2.67% (Lwr)	25mg (Upr), -13mg (Lwr)
526 - 575	550	4.35% (Upr)" , -4.56% (Lwr)	25mg (Upr), -24mg (Lwr)
576 - 625	600	4.00% (Upr)" , -4.17% (Lwr)	25mg (Upr), -24mg (Lwr)
626 - 675	650	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)
676 - 725	700	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)
726 - 775	750	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)
776 - 825	800	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)
826 - 875	850	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)
876 - 925	900	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)
926 - 975	950	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)
976 - 1050	1000	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	1100	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

BEVACIZUMAB IV INFUSION (Version 2) continued:			
1251 - 1350	1300	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1450	1400	3.45% (Upr)" , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)
1451 - 1575	1500	4.76% (Upr)" , -3.38% (Lwr)	75mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

MONOCLONALS – CETUXIMAB IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 5mg/ml concentration of cetuximab.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
365 - 400	385	3.75% (Upr)" , -5.00% (Lwr)	15mg (Upr), -20mg (Lwr)
401 - 440	420	4.55% (Upr)" , -4.32% (Lwr)	20mg (Upr), -19mg (Lwr)
441 - 480	460	4.17% (Upr)" , -3.96% (Lwr)	20mg (Upr), -19mg (Lwr)
481 - 520	500	3.85% (Upr)" , -3.65% (Lwr)	20mg (Upr), -19mg (Lwr)
521 - 560	540	3.57% (Upr)" , -3.39% (Lwr)	20mg (Upr), -19mg (Lwr)
561 - 610	590	3.28% (Upr)" , -4.75% (Lwr)	20mg (Upr), -29mg (Lwr)
611 - 670	640	4.48% (Upr)" , -4.33% (Lwr)	30mg (Upr), -29mg (Lwr)
671 - 730	700	4.11% (Upr)" , -3.97% (Lwr)	30mg (Upr), -29mg (Lwr)
731 - 790	760	3.80% (Upr)" , -3.67% (Lwr)	30mg (Upr), -29mg (Lwr)
791 - 870	830	4.60% (Upr)" , -4.48% (Lwr)	40mg (Upr), -39mg (Lwr)
871 - 950	910	4.21% (Upr)" , -4.11% (Lwr)	40mg (Upr), -39mg (Lwr)
951 - 1050	1000	4.76% (Upr)" , -4.67% (Lwr)	50mg (Upr), -49mg (Lwr)
1051 - 1150	1100	4.35% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

MONOCLONALS - DARATUMUMAB INFUSION (Version 1)

The dose bands used in this table are constructed based on a 20mg/ml concentration of daratumumab.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
400 - 439	420	4.33% (Upr)" , -5.00% (Lwr)	19mg (Upr), -20mg (Lwr)
440 - 479	460	3.97% (Upr)" , -4.55% (Lwr)	19mg (Upr), -20mg (Lwr)
480 - 529	500	5.48% (Upr)" , -4.17% (Lwr)	29mg (Upr), -20mg (Lwr)
530 - 579	560	3.28% (Upr)" , -5.66% (Lwr)	19mg (Upr), -30mg (Lwr)
580 - 629	600	4.61% (Upr)" , -3.45% (Lwr)	29mg (Upr), -20mg (Lwr)
630 - 689	660	4.21% (Upr)" , -4.76% (Lwr)	29mg (Upr), -30mg (Lwr)
690 - 750	720	4.00% (Upr)" , -4.35% (Lwr)	30mg (Upr), -30mg (Lwr)
751 - 810	780	3.70% (Upr)" , -3.86% (Lwr)	30mg (Upr), -29mg (Lwr)
811 - 880	840	4.55% (Upr)" , -3.58% (Lwr)	40mg (Upr), -29mg (Lwr)
881 - 960	920	4.17% (Upr)" , -4.43% (Lwr)	40mg (Upr), -39mg (Lwr)
961 - 1050	1000	4.76% (Upr)" , -4.06% (Lwr)	50mg (Upr), -39mg (Lwr)
1051 - 1150	1100	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	1300	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1470	1400	4.76% (Upr)" , -3.63% (Lwr)	70mg (Upr), -49mg (Lwr)
1471 - 1600	1540	3.75% (Upr)" , -4.69% (Lwr)	60mg (Upr), -69mg (Lwr)
1601 - 1740	1680	3.45% (Upr)" , -4.93% (Lwr)	60mg (Upr), -79mg (Lwr)
1741 - 1900	1820	4.21% (Upr)" , -4.54% (Lwr)	80mg (Upr), -79mg (Lwr)
1901 - 2100	2000	4.76% (Upr)" , -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)
2101 - 2300	2200	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

MONOCLONALS – IPILIMUMAB IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 5mg/ml concentration of ipilimumab.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
39 - 42	40	4.76% (Upr)" , -2.56% (Lwr)	2mg (Upr), -1mg (Lwr)
43 - 47	45	4.26% (Upr)" , -4.65% (Lwr)	2mg (Upr), -2mg (Lwr)
48 - 52	50	3.85% (Upr)" , -4.17% (Lwr)	2mg (Upr), -2mg (Lwr)
53 - 57	55	3.51% (Upr)" , -3.77% (Lwr)	2mg (Upr), -2mg (Lwr)
58 - 62	60	3.23% (Upr)" , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)
63 - 67	65	2.99% (Upr)" , -3.17% (Lwr)	2mg (Upr), -2mg (Lwr)
68 - 72	70	2.78% (Upr)" , -2.94% (Lwr)	2mg (Upr), -2mg (Lwr)
73 - 77	75	2.60% (Upr)" , -2.74% (Lwr)	2mg (Upr), -2mg (Lwr)
78 - 82	80	2.44% (Upr)" , -2.56% (Lwr)	2mg (Upr), -2mg (Lwr)
83 - 87	85	2.30% (Upr)" , -2.41% (Lwr)	2mg (Upr), -2mg (Lwr)
88 - 92	90	2.17% (Upr)" , -2.27% (Lwr)	2mg (Upr), -2mg (Lwr)
93 - 97	95	2.06% (Upr)" , -2.15% (Lwr)	2mg (Upr), -2mg (Lwr)
98 - 105	100	4.76% (Upr)" , -2.04% (Lwr)	5mg (Upr), -2mg (Lwr)
106 - 115	110	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)
116 - 125	120	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	130	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	140	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 155	150	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)
156 - 165	160	3.03% (Upr)" , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)
166 - 175	170	2.86% (Upr)" , -2.41% (Lwr)	5mg (Upr), -4mg (Lwr)
176 - 185	180	2.70% (Upr)" , -2.27% (Lwr)	5mg (Upr), -4mg (Lwr)
186 - 195	190	2.56% (Upr)" , -2.15% (Lwr)	5mg (Upr), -4mg (Lwr)
196 - 210	200	4.76% (Upr)" , -2.04% (Lwr)	10mg (Upr), -4mg (Lwr)
211 - 230	220	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)
231 - 250	240	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)
251 - 270	260	3.70% (Upr)" , -3.59% (Lwr)	10mg (Upr), -9mg (Lwr)
271 - 290	280	3.45% (Upr)" , -3.32% (Lwr)	10mg (Upr), -9mg (Lwr)
291 - 310	300	3.23% (Upr)" , -3.09% (Lwr)	10mg (Upr), -9mg (Lwr)
311 - 330	320	3.03% (Upr)" , -2.89% (Lwr)	10mg (Upr), -9mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

IPILIMUMAB IV INFUSION (Version 2) continued:			
331 - 350	340	2.86% (Upr)" , -2.72% (Lwr)	10mg (Upr), -9mg (Lwr)
351 - 370	360	2.70% (Upr)" , -2.56% (Lwr)	10mg (Upr), -9mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

MONOCLONALS – NIVOLUMAB IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 10mg/ml concentration of nivolumab.

Dose Range (mg)	Banded dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
39 - 42	40	4.76% (Upr)" , -2.56% (Lwr)	2mg (Upr), -1mg (Lwr)
43 - 46	44	4.35% (Upr)" , -2.33% (Lwr)	2mg (Upr), -1mg (Lwr)
47 - 50	48	4.00% (Upr)" , -2.13% (Lwr)	2mg (Upr), -1mg (Lwr)
51 - 55	52	5.45% (Upr)" , -1.96% (Lwr)	3mg (Upr), -1mg (Lwr)
56 - 61	58	4.92% (Upr)" , -3.57% (Lwr)	3mg (Upr), -2mg (Lwr)
62 - 67	64	4.48% (Upr)" , -3.23% (Lwr)	3mg (Upr), -2mg (Lwr)
68 - 73	70	4.11% (Upr)" , -2.94% (Lwr)	3mg (Upr), -2mg (Lwr)
74 - 79	76	3.80% (Upr)" , -2.70% (Lwr)	3mg (Upr), -2mg (Lwr)
80 - 85	82	3.53% (Upr)" , -2.50% (Lwr)	3mg (Upr), -2mg (Lwr)
86 - 95	90	5.26% (Upr)" , -4.65% (Lwr)	5mg (Upr), -4mg (Lwr)
96 - 105	100	4.76% (Upr)" , -4.17% (Lwr)	5mg (Upr), -4mg (Lwr)
106 - 115	110	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)
116 - 125	120	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	130	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 147	140	4.76% (Upr)" , -2.94% (Lwr)	7mg (Upr), -4mg (Lwr)
148 - 162	154	4.94% (Upr)" , -4.05% (Lwr)	8mg (Upr), -6mg (Lwr)
163 - 177	170	3.95% (Upr)" , -4.29% (Lwr)	7mg (Upr), -7mg (Lwr)
178 - 190	186	2.11% (Upr)" , -4.49% (Lwr)	4mg (Upr), -8mg (Lwr)
191 - 210	200	4.76% (Upr)" , -4.71% (Lwr)	10mg (Upr), -9mg (Lwr)
211 - 230	220	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)
231 - 250	240	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)
251 - 270	260	3.70% (Upr)" , -3.59% (Lwr)	10mg (Upr), -9mg (Lwr)
271 - 290	280	3.45% (Upr)" , -3.32% (Lwr)	10mg (Upr), -9mg (Lwr)
291 - 315	300	4.76% (Upr)" , -3.09% (Lwr)	15mg (Upr), -9mg (Lwr)
316 - 345	330	4.35% (Upr)" , -4.43% (Lwr)	15mg (Upr), -14mg (Lwr)
346 - 378	360	4.76% (Upr)" , -4.05% (Lwr)	18mg (Upr), -14mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

MONOCLONALS – PANITUMUMAB IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 20mg/ml concentration of panitumumab.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
250 - 269	260	3.46% (Upr)", -3.85% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	280	3.21% (Upr)", -3.57% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	300	3.00% (Upr)", -3.33% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	320	2.81% (Upr)", -3.13% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	340	2.65% (Upr)", -2.94% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	360	5.28% (Upr)", -2.78% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 419	400	4.75% (Upr)", -5.00% (Lwr)	19mg (Upr), -20mg (Lwr)
420 - 459	440	4.32% (Upr)", -4.55% (Lwr)	19mg (Upr), -20mg (Lwr)
460 - 499	480	3.96% (Upr)", -4.17% (Lwr)	19mg (Upr), -20mg (Lwr)
500 - 539	520	3.65% (Upr)", -3.85% (Lwr)	19mg (Upr), -20mg (Lwr)
540 - 579	560	3.39% (Upr)", -3.57% (Lwr)	19mg (Upr), -20mg (Lwr)
580 - 619	600	3.17% (Upr)", -3.33% (Lwr)	19mg (Upr), -20mg (Lwr)
620 - 659	640	2.97% (Upr)", -3.13% (Lwr)	19mg (Upr), -20mg (Lwr)
660 - 709	680	4.26% (Upr)", -2.94% (Lwr)	29mg (Upr), -20mg (Lwr)
710 - 769	740	3.92% (Upr)", -4.05% (Lwr)	29mg (Upr), -30mg (Lwr)
770 - 829	800	3.63% (Upr)", -3.75% (Lwr)	29mg (Upr), -30mg (Lwr)
830 - 890	860	3.49% (Upr)", -3.49% (Lwr)	30mg (Upr), -30mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

MONOCLONALS – RITUXIMAB IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 10mg/ml concentration of riTUXimab.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
475 - 525	500	4.76% (Upr)" , -5.26% (Lwr)	25mg (Upr), -25mg (Lwr)
526 - 575	550	4.35% (Upr)" , -4.56% (Lwr)	25mg (Upr), -24mg (Lwr)
576 - 625	600	4.00% (Upr)" , -4.17% (Lwr)	25mg (Upr), -24mg (Lwr)
626 - 675	650	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)
676 - 725	700	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)
726 - 775	750	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)
776 - 825	800	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)
826 - 875	850	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)
876 - 925	900	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)
926 - 975	950	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)
976 - 1050	1000	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	1100	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	1200	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	1300	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

MONOCLONALS - TRASTUZUMAB IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 21mg/ml concentration of trastuzumab.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
95 - 115	105	8.70% (Upr)" , -10.53% (Lwr)	10mg (Upr), -10mg (Lwr)
116 - 136	126	7.35% (Upr)" , -8.62% (Lwr)	10mg (Upr), -10mg (Lwr)
137 - 157	147	6.37% (Upr)" , -7.30% (Lwr)	10mg (Upr), -10mg (Lwr)
158 - 178	168	5.62% (Upr)" , -6.33% (Lwr)	10mg (Upr), -10mg (Lwr)
179 - 199	189	5.03% (Upr)" , -5.59% (Lwr)	10mg (Upr), -10mg (Lwr)
200 - 220	210	4.55% (Upr)" , -5.00% (Lwr)	10mg (Upr), -10mg (Lwr)
221 - 241	231	4.15% (Upr)" , -4.52% (Lwr)	10mg (Upr), -10mg (Lwr)
242 - 262	252	3.82% (Upr)" , -4.13% (Lwr)	10mg (Upr), -10mg (Lwr)
263 - 283	273	3.53% (Upr)" , -3.80% (Lwr)	10mg (Upr), -10mg (Lwr)
284 - 314	294	6.37% (Upr)" , -3.52% (Lwr)	20mg (Upr), -10mg (Lwr)
315 - 346	336	2.89% (Upr)" , -6.67% (Lwr)	10mg (Upr), -21mg (Lwr)
347 - 367	357	2.72% (Upr)" , -2.88% (Lwr)	10mg (Upr), -10mg (Lwr)
368 - 388	378	2.58% (Upr)" , -2.72% (Lwr)	10mg (Upr), -10mg (Lwr)
389 - 419	399	4.77% (Upr)" , -2.57% (Lwr)	20mg (Upr), -10mg (Lwr)
420 - 461	441	4.34% (Upr)" , -5.00% (Lwr)	20mg (Upr), -21mg (Lwr)
462 - 514	483	6.03% (Upr)" , -4.55% (Lwr)	31mg (Upr), -21mg (Lwr)
515 - 566	546	3.53% (Upr)" , -6.02% (Lwr)	20mg (Upr), -31mg (Lwr)
567 - 618	588	4.85% (Upr)" , -3.70% (Lwr)	30mg (Upr), -21mg (Lwr)
619 - 683	651	4.69% (Upr)" , -5.17% (Lwr)	32mg (Upr), -32mg (Lwr)
684 - 755	714	5.43% (Upr)" , -4.39% (Lwr)	41mg (Upr), -30mg (Lwr)
756 - 839	798	4.89% (Upr)" , -5.56% (Lwr)	41mg (Upr), -42mg (Lwr)
840 - 933	882	5.47% (Upr)" , -5.00% (Lwr)	51mg (Upr), -42mg (Lwr)
934 - 1040	987	5.10% (Upr)" , -5.67% (Lwr)	53mg (Upr), -53mg (Lwr)

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOSE BANDING TABLES – ORAL ANTI-CANCER MEDICATIONS:

CAPECITABINE (Version 3)

The dose bands used in this table are constructed based on combinations of 500mg, 300mg and 150mg capecitabine tablets. Dose rounding has been applied to this table in order to facilitate the nearest measurable combination of tablets available.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Tablets needed:
750 - 850	800	5.88% (Upr)", -5.88% (Lwr)	50mg (Upr), -50mg (Lwr)	1x500mg and 1x300mg
851 - 950	900	5.26% (Upr)", -5.16% (Lwr)	50mg (Upr), -49mg (Lwr)	3x300mg
951 - 1075	1000	6.98% (Upr)", -4.56% (Lwr)	75mg (Upr), -49mg (Lwr)	2x500mg
1076 - 1200	1150	4.17% (Upr)", -6.17% (Lwr)	50mg (Upr), -74mg (Lwr)	2x500mg and 1x150mg
1201 - 1375	1300	5.45% (Upr)", -7.20% (Lwr)	75mg (Upr), -99mg (Lwr)	2x500mg and 1x300mg
1376 - 1475	1450	1.69% (Upr)", -5.02% (Lwr)	25mg (Upr), -74mg (Lwr)	2x500mg, 3x150mg
1476 - 1550	1500	3.23% (Upr)", -1.55% (Lwr)	50mg (Upr), -24mg (Lwr)	3x500mg
1551 - 1700	1600	5.88% (Upr)", -2.88% (Lwr)	100mg (Upr), -49mg (Lwr)	2x500mg and 2x300mg
1701 - 1900	1800	5.26% (Upr)", -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)	3x500mg and 1x300mg
1901 - 2075	2000	3.61% (Upr)", -4.77% (Lwr)	75mg (Upr), -99mg (Lwr)	4x500mg
2076 - 2225	2150	3.37% (Upr)", -3.33% (Lwr)	75mg (Upr), -74mg (Lwr)	4x500mg and 1x150mg
2226 - 2400	2300	4.17% (Upr)", -3.08% (Lwr)	100mg (Upr), -74mg (Lwr)	4x500mg, 1x 300mg
2401 - 2575	2500	2.91% (Upr)", -3.84% (Lwr)	75mg (Upr), -99mg (Lwr)	5x500mg
2576 - 2775	2650	4.50% (Upr)", -2.67% (Lwr)	125mg (Upr), -74mg (Lwr)	5x500mg and 1x150mg
2776 - 2900	2800	3.45% (Upr)", -0.83% (Lwr)	100mg (Upr), -24mg (Lwr)	5x500mg, 1x300mg

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

Version Control Table

Version	Date	Amendment	Approved By
1	03/06/2016	Version 1	Working Group
2	06/07/2017	<ul style="list-style-type: none"> Amendment to maximum variation range (%) calculation to keep in line with NCCP dose banding guidance documentation 2016 Expansion of existing tables: <ul style="list-style-type: none"> Carboplatin (v2) Cetuximab (v2) Cyclophosphamide IVB (v2) Cyclophosphamide infusion (v2) Docetaxel (v2) Doxorubicin (v2) Epirubicin (v2) 5-Fluorouracil IVB (v2) 5-Fluorouracil Infusors (v2) Oxaliplatin (v2) Rituximab (v2) Addition of new tables: <ul style="list-style-type: none"> Azacitidine (v1) Bortezomib 2.5mg/ml (v1) Bendamustine (v1) Cisplatin (v1) Cytarabine 100mg/ml (v1) Etoposide (v1) Methotrexate 100mg/ml (v1) Pembrolizumab (v1) Pemetrexed (v1) Vinorelbine (v1) 	Working Group
3	16/8/2018	<ul style="list-style-type: none"> Expansion of existing tables <ul style="list-style-type: none"> 5-Fluorouracil Infusors (including note regarding SV2.5 infusors) (v3) Gemcitabine 38mg/ml (v3) Gemcitabine 40mg/ml (v3) Addition of new tables <ul style="list-style-type: none"> Daratumumab (v1) Dacarbazine (v1) 	Working group
4	23/08/2019	<ul style="list-style-type: none"> Removal of pembrolizumab (Now flat dosing) Expansion of existing tables <ul style="list-style-type: none"> Carboplatin (v3) Gemcitabine 38mg/ml (v4) Gemcitabine 40mg/ml (v4) Oxaliplatin (v3) Addition of new tables: <ul style="list-style-type: none"> Mitomycin (v1) Bleomycin (v1) Carfilzomib (v1) Ipilimumab (v1) Nab-Paclitaxel (v1) Trastuzumab emtansine (v1) 	Working group
5	01/03/2022	<ul style="list-style-type: none"> Inclusion of details of COVID-19 Dose Banding Tables Inclusion of Tall Man lettering Expansion of existing table: <ul style="list-style-type: none"> CISplatin (v2) Modification of table: <ul style="list-style-type: none"> Bleomycin (v2): Removed reference to bleomycin mg dosing Addition of new table: <ul style="list-style-type: none"> Panitumumab (v1) 	NCCP

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

6	01/02/2023	<ul style="list-style-type: none"> • Expansion / amendment of existing table <ul style="list-style-type: none"> – Methotrexate 100mg/ml (v2) <ul style="list-style-type: none"> ○ Dose bands amended to 1500mg, 1700mg, 1800mg and 2600mg 	<ul style="list-style-type: none"> • Addition of new table: <ul style="list-style-type: none"> – Gemcitabine 100mg/ml (v1) 	NCCP
7	22/11/2024	<ul style="list-style-type: none"> • Expansion / amendment of existing tables <ul style="list-style-type: none"> – Bleomycin (v3) - dose ranges updated to remove gaps – CARBOplatin (v4) - dose bands added to take into account capping of CrCl @125mL/min: 300mg, 450mg, 750mg, 900mg, 1050mg – Cytarabine (v2) - amended to take into account measurability for compounding – Ipilimumab (v2) - expanded to allow for 1mg/kg dosing – Capecitabine (v3) – correction of minor typo 	<ul style="list-style-type: none"> • Addition of new tables: <ul style="list-style-type: none"> – Cabazitaxel (v1) – DOXOrubicin pegylated liposomal (v1) – Ifosfamide (v1) – Methotrexate syringes (v1) – Nivolumab (v1) – Topotecan (v1) – Vinblastine (v1) – VinCRISTine (v1) 	NCCP

NCCP Dose Banding Tables	Published: 29/11/2024	Version: 7
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		